

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> C12N 15/86, A61K 48/00, C07K 14/47, 14/775	<b>A2</b>	<b>(11) International Publication Number:</b> WO 96/13598 <b>(43) International Publication Date:</b> 9 May 1996 (09.05.96)
<b>(21) International Application Number:</b> PCT/US95/14018 <b>(22) International Filing Date:</b> 27 October 1995 (27.10.95)  <b>(30) Priority Data:</b> 08/331,384 28 October 1994 (28.10.94) US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/331,384 (CIP) Filed on 28 October 1994 (28.10.94)  <b>(71) Applicant (for all designated States except US):</b> THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 133 South 36th Street, Philadelphia, PA 19104-3246 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WILSON, James, M. [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US). KELLEY, William, M. [US/US]; 14 Hemlock Road, Lansdowne, PA 19050 (US). FISHER, Krishna, J. [US/US]; 4006 Pine Street, Philadelphia, PA 19104 (US).	<b>(74) Agents:</b> BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, Spring House, PA 19477 (US).  <b>(81) Designated States:</b> AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
<b>(54) Title:</b> HYBRID ADENOVIRUS-AAV VIRUS AND METHOD OF USE THEREOF  <b>(57) Abstract</b>  The present invention provides a hybrid vector construct which comprises a portion of an adenovirus, 5' and 3' ITR sequences from an AAV, and a selected transgene. Also provided is a hybrid virus linked via a polycation conjugate to an AAV <i>rep</i> gene to form a single particle. These trans-infection particles are characterized by high titer transgene delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome. Also disclosed is the use of the hybrid vectors and viruses to produce large quantities of recombinant AAV.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## HYBRID ADENOVIRUS-AAV VIRUS AND METHODS OF USE THEREOF

This invention was supported by the National  
Institute of Health Grant No. P30 DK 47757. The United  
5 States government has rights in this invention.

Field of the Invention

The present invention relates to the field of  
vectors useful in somatic gene therapy and the production  
10 thereof.

Background of the Invention

Recombinant adenoviruses are capable of  
providing extremely high levels of transgene delivery to  
15 virtually all cell types, regardless of the mitotic  
state. High titers ( $10^{13}$  plaque forming units/ml) of  
recombinant virus can be easily generated in 293 cells  
(the adenovirus equivalent to retrovirus packaging cell  
lines) and cryo-stored for extended periods without  
20 appreciable losses.

The primary limitation of this virus as a  
vector resides in the complexity of the adenovirus  
genome. A human adenovirus is comprised of a linear,  
approximately 36 kb double-stranded DNA genome, which is  
25 divided into 100 map units (m.u.), each of which is 360  
bp in length. The DNA contains short inverted terminal  
repeats (ITR) at each end of the genome that are required  
for viral DNA replication. The gene products are  
organized into early (E1 through E4) and late (L1 through  
30 L5) regions, based on expression before or after the  
initiation of viral DNA synthesis [see, e.g., Horwitz,  
Virology, 2d edit., ed. B. N. Fields, Raven Press, Ltd.,  
New York (1990)].

A human adenovirus undergoes a highly regulated  
35 program during its normal viral life cycle [Y. Yang et  
al, Proc. Natl. Acad. Sci., USA, 91:4407-4411 (1994)].

Virions are internalized by receptor-mediated endocytosis and transported to the nucleus where the immediate early genes, E1a and E1b, are expressed. Because these early gene products regulate expression of a variety of host genes (which prime the cell for virus production) and are central to the cascade activation of early delayed genes (e.g. E2, E3, and E4) followed by late genes (e.g. L1-5), first generation recombinant adenoviruses for gene therapy focused on the removal of the E1 domain. This strategy was successful in rendering the vectors replication defective, however, in vivo studies revealed transgene expression was transient and invariably associated with the development of severe inflammation at the site of vector targeting [S. Ishibashi et al, J. Clin. Invest., 93:1885-1893 (1994); J. M. Wilson et al, Proc. Natl. Acad. Sci., USA, 85:4421-4424 (1988); J. M. Wilson et al, Clin. Bio., 3:21-26 (1991); M. Grossman et al, Som. Cell. and Mol. Gen., 17:601-607 (1991)].

Adeno-associated viruses (AAV) have also been employed as vectors. AAV is a small, single-stranded (ss) DNA virus with a simple genomic organization (4.7 kb) that makes it an ideal substrate for genetic engineering. Two open reading frames encode a series of rep and cap polypeptides. Rep polypeptides (rep78, rep68, rep62 and rep40) are involved in replication, rescue and integration of the AAV genome. The cap proteins (VP1, VP2 and VP3) form the virion capsid. Flanking the rep and cap open reading frames at the 5' and 3' ends are 145 bp inverted terminal repeats (ITRs), the first 125 bp of which are capable of forming Y- or T-shaped duplex structures. Of importance for the development of AAV vectors, the entire rep and cap domains can be excised and replaced with a therapeutic or reporter transgene [B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp.155-168

(1990)]. It has been shown that the ITRs represent the minimal sequence required for replication, rescue, packaging, and integration of the AAV genome.

The AAV life cycle is biphasic, composed of both latent and lytic episodes. During a latent infection, AAV virions enter a cell as an encapsidated ssDNA, and shortly thereafter are delivered to the nucleus where the AAV DNA stably integrates into a host chromosome without the apparent need for host cell division. In the absence of helper virus, the integrated ss DNA AAV genome remains latent but capable of being activated and rescued. The lytic phase of the life cycle begins when a cell harboring an AAV provirus is challenged with a secondary infection by a herpesvirus or adenovirus which encodes helper functions that are recruited by AAV to aid in its excision from host chromatin [B. J. Carter, cited above]. The infecting parental ssDNA is expanded to duplex replicating form (RF) DNAs in a rep dependent manner. The rescued AAV genomes are packaged into preformed protein capsids (icosahedral symmetry approximately 20 nm in diameter) and released as infectious virions that have packaged either + or - ss DNA genomes following cell lysis.

Progress towards establishing AAV as a transducing vector for gene therapy has been slow for a variety of reasons. While the ability of AAV to integrate in quiescent cells is important in terms of long term expression of a potential transducing gene, the tendency of the integrated provirus to preferentially target only specific sites in chromosome 19 reduces its usefulness. Additionally, difficulties surround large-scale production of replication defective recombinants. In contrast to the production of recombinant retrovirus or adenovirus, the only widely recognized means for manufacturing transducing AAV virions entails co-

transfection with two different, yet complementing plasmids. One of these contains the therapeutic or reporter minigene sandwiched between the two cis acting AAV ITRs. The AAV components that are needed for rescue and subsequent packaging of progeny recombinant genomes are provided in trans by a second plasmid encoding the viral open reading frames for rep and cap proteins. The cells targeted for transfection must also be infected with adenovirus thus providing the necessary helper functions. Because the yield of recombinant AAV is dependent on the number of cells that are transfected with the cis- and trans-acting plasmids, it is desirable to use a transfection protocol with high efficiency. For large-scale production of high titer virus, however, previously employed high efficiency calcium phosphate and liposome systems are cumbersome and subject to inconsistencies.

There remains a need in the art for the development of vectors which overcome the disadvantages of the known vector systems.

#### Summary of the Invention

In one aspect, the present invention provides a unique recombinant hybrid adenovirus/AAV virus, which comprises an adenovirus capsid containing selected portions of an adenovirus sequence, 5' and 3' AAV ITR sequences which flank a selected transgene under the control of a selected promoter and other conventional vector regulatory components. This hybrid virus is characterized by high titer transgene delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome in the presence of the rep gene. In one embodiment, the transgene is a reporter gene. Another embodiment of the hybrid virus contains a therapeutic transgene. In a preferred embodiment, the

hybrid virus has associated therewith a polycation sequence and the AAV rep gene. This construct is termed the hybrid virus conjugate or trans-infection particle.

In another aspect, the present invention  
5 provides a hybrid vector construct for use in producing the hybrid virus or viral particle described above. This hybrid vector comprises selected portions of an adenovirus sequence, 5' and 3' AAV ITR sequences which flank a selected transgene under the control of a  
10 selected promoter and other conventional vector regulatory components.

In another aspect, the invention provides a composition comprising a hybrid viral particle for use in delivering a selected gene to a host cell. Such a  
15 composition may be employed to deliver a therapeutic gene to a targeted host cell to treat or correct a genetically associated disorder or disease.

In yet another aspect, the present invention provides a method for producing the hybrid virus by  
20 transfecting a suitable packaging cell line with the hybrid vector construct of this invention. In another embodiment the method involves co-transfecting a cell line (either a packaging cell line or a non-packaging cell line) with a hybrid vector construct and a suitable  
25 helper virus.

In a further aspect, the present invention provides a method for producing large quantities of recombinant AAV particles with high efficiency by employing the above methods, employing the hybrid vector  
30 construct of this invention and collecting the rAAV particles from a packaging cell line transfected with the vector.

Other aspects and advantages of the present invention are described further in the following detailed  
35 description of the preferred embodiments thereof.

Brief Description of the Drawings

Fig. 1A is a schematic diagram of a vector construct pAd.AV.CMVLacZ [SEQ ID NO: 1], which contains (from the top in clockwise order) adenovirus sequence map units 0-1 (clear bar); the 5' AAV ITR (solid bar); a CMV immediate early enhancer/promoter (hatched arrow), an SV40 intron (clear bar), an *E. coli* beta-galactosidase cDNA (LacZ) (hatched line), an SV40 polyadenylation signal (clear bar), a 3' AAV ITR (solid bar), adenovirus sequence from map units 9-16 (clear bar), and a portion of a pBR322 derivative plasmid (thin solid line). Restriction endonuclease enzymes are identified by their conventional designations; and the location of each restriction enzyme is identification by the nucleotide number in parentheses to the right of the enzyme designation.

Fig. 1B is a schematic drawing demonstrating linearization of pAd.AV.CMVLacZ [SEQ ID NO: 1] by digestion with restriction enzyme NheI and a linear arrangement of a ClaI digested adenovirus type 5 with deletions from mu 0-1. The area where homologous recombination will occur (between m.u. 9-16) in both the plasmid and adenovirus sequences is indicated by crossed lines.

Fig. 1C is a schematic drawing which demonstrates the hybrid virus Ad.AV.CMVLacZ after co-transfection of the linearized pAd.AV.CMVLacZ [SEQ ID NO: 1] and adenovirus into 293 cells followed by intracellular homologous recombination.

Fig. 2A-2K report the top DNA strand of the double-strand plasmid pAd.AV.CMVLacZ [SEQ ID NO: 1] (the complementary strand can be readily derived by one of skill in the art). With reference to SEQ ID NO: 1, nucleotides 1-365 are adenovirus type 5 sequences; the 5' AAV ITR sequence spans nucleotides 366-538; the CMV

promoter/enhancer spans nucleotides 563-1157; the SV-40 intron spans nucleotides 1158-1179; the *LacZ* gene spans nucleotides 1356-4827; the SV-40 poly A sequence spans nucleotides 4839-5037; the 3' AAV ITR spans nucleotides 5053 to 5221; nucleotides 5221 to about 8100 are adenovirus type 5 sequences. The remaining sequences are non-specific/plasmid sequences.

Fig. 3 is a bar graph plotting u.v. absorbance at 420 nm of the beta-galactosidase blue color for a control and ten putative positive clones (D1A through D1J) of 293 cells transfected with the recombinant hybrid Ad.AV.CMVLacZ. Eight of the clones expressed high levels of enzyme.

Fig. 4 is a schematic diagram of pRep78/52 [SEQ ID NO: 2]. This plasmid includes an AAV P5 promoter, Rep78, Rep52 and a poly-A sequence in a pUC18 plasmid background.

Figs. 5A - 5E report nucleotides 1-4910 of the top DNA strand of the double-strand plasmid pRep78/52 [SEQ ID NO: 2] (the complementary strand can be readily derived by one of skill in the art).

Fig. 6 is a flow diagram of the construction of a trans-infection particle formed by a hybrid virus, a poly-L-lysine sequence and attached AAV rep-containing plasmid.

Fig. 7 is a flow diagram of the hybrid virus' life cycle, in which a trans-infection particle enters the cell and is transported to the nucleus. The virus is uncoated and the rep mediates rescue of the inserted gene, which is then integrated into the chromosome of the host cell.

Detailed Description of the Invention

The present invention provides a unique gene transfer vehicle which overcomes many of the limitations of prior art viral vectors. This engineered hybrid virus contains selected adenovirus domains and selected AAV domains as well as a selected transgene and regulatory elements in a viral capsid. This novel hybrid virus solves the problems observed with other, conventional gene therapy viruses, because it is characterized by the ability to provide extremely high levels of transgene delivery to virtually all cell types (conferred by its adenovirus sequence) and the ability to provide stable long-term transgene integration into the host cell (conferred by its AAV sequences). The adenovirus-AAV hybrid virus of this invention has utility both as a novel gene transfer vehicle and as a reagent in a method for large-scale recombinant AAV production.

In a preferred embodiment, a trans-infection particle or hybrid virus conjugate composed of the hybrid Ad/AAV virus conjugated to a rep expression plasmid via a poly-lysine bridge is provided. This trans-infection particle is advantageous because the adenovirus carrier can be grown to titers sufficient for high MOI infections of a large number of cells, the adenoviral genome is efficiently transported to the nucleus in nondividing cells as a complex facilitating transduction into mitotically quiescent cells, and incorporation of the rep plasmid into the trans-infection particle provides high but transient expression of rep that is necessary for both rescue of rAAV DNA and efficient and site-specific integration.

**I. Construction of the Hybrid Vector and Virus****A. The Adenovirus Component of the Vector and Virus**

The hybrid virus of this invention uses  
5 adenovirus nucleic acid sequences as a shuttle to deliver  
a recombinant AAV/transgene genome to a target cell. The  
DNA sequences of a number of adenovirus types, including  
type Ad5, are available from Genbank. The adenovirus  
sequences may be obtained from any known adenovirus type,  
10 including the presently identified 41 human types  
[Horwitz et al, cited above]. Similarly adenoviruses  
known to infect other animals may also be employed in the  
vector constructs of this invention. The selection of  
the adenovirus type is not anticipated to limit the  
15 following invention. A variety of adenovirus strains are  
available from the American Type Culture Collection,  
Rockville, Maryland, or available by request from a  
variety of commercial and institutional sources. In the  
following exemplary embodiment an adenovirus, type 5  
20 (Ad5) is used for convenience.

The adenovirus nucleic acid sequences  
employed in the hybrid vector of this invention can range  
from a minimum sequence amount, which requires the use of  
a helper virus to produce the hybrid virus particle, to  
25 only selected deletions of adenovirus genes, which  
deleted gene products can be supplied in the hybrid viral  
production process by a selected packaging cell.  
Specifically, at a minimum, the adenovirus nucleic acid  
sequences employed in the pAdΔ shuttle vector of this  
30 invention are adenovirus genomic sequences from which all  
viral genes are deleted and which contain only those  
adenovirus sequences required for packaging adenoviral  
genomic DNA into a preformed capsid head. More  
specifically, the adenovirus sequences employed are the  
35 cis-acting 5' and 3' inverted terminal repeat (ITR)

10

sequences of an adenovirus (which function as origins of replication) and the native 5' packaging/enhancer domain, that contains sequences necessary for packaging linear Ad genomes and enhancer elements for the E1 promoter.

5 According to this invention, the entire adenovirus 5' sequence containing the 5' ITR and packaging/enhancer region can be employed as the 5' adenovirus sequence in the hybrid virus. This left terminal (5') sequence of the Ad5 genome useful in this invention spans bp 1 to  
10 about 360 of the conventional adenovirus genome, also referred to as map units 0-1 of the viral genome, and generally is from about 353 to about 360 nucleotides in length. This sequence includes the 5' ITR (bp 1-103 of the adenovirus genome); and the packaging/enhancer domain  
15 (bp 194-358 of the adenovirus genome). Preferably, this native adenovirus 5' region is employed in the hybrid virus and vector in unmodified form. Alternatively, corresponding sequences from other adenovirus types may be substituted. These Ad sequences may be modified to  
20 contain desired deletions, substitutions, or mutations, provided that the desired function is not eliminated.

The 3' adenovirus sequences of the hybrid virus include the right terminal (3') ITR sequence of the adenoviral genome spanning about bp 35,353 - end of the  
25 adenovirus genome, or map units -98.4-100. This sequence is generally about 580 nucleotide in length. This entire sequence is desirably employed as the 3' sequence of a hybrid virus. Preferably, the native adenovirus 3' region is employed in the hybrid virus in unmodified  
30 form. However, as described above with respect to the 5' sequences, some modifications to these sequences which do not adversely effect their biological function may be acceptable. As described below, when these 5' and 3' adenovirus sequences are employed in the hybrid vector, a  
35 helper adenovirus which supplies all other essential

genes for viral formation alone or with a packaging cell line is required in the production of the hybrid virus or viral particle.

Alternative embodiments of the hybrid virus employ adenovirus sequences in addition to the minimum sequences, but which contain deletions of all or portions of adenovirus genes. For example, the adenovirus immediate early gene E1a (which spans mu 1.3 to 4.5) and delayed early gene E1b (which spans mu 4.6 to 11.2) should be deleted from the adenovirus sequence which forms a part of the hybrid vector construct and virus. Alternatively, if these sequences are not completely eliminated, at least a sufficient portion of the E1a and E1b sequences must be deleted so as to render the virus replication defective. These deletions, whether complete or partial, which eliminate the biological function of the gene are termed "functional deletions" herein.

Additionally, all or a portion of the adenovirus delayed early gene E3 (which spans mu 76.6 to 86.2) may be eliminated from the adenovirus sequence which forms a part of the hybrid virus. The function of E3 is irrelevant to the function and production of the hybrid virus.

All or a portion of the adenovirus delayed early gene E2a (which spans mu 67.9 to 61.5) may be eliminated from the hybrid virus. It is also anticipated that portions of the other delayed early genes E2b (which spans mu 29 to 14.2) and E4 (which spans mu 96.8 to 91.3) may also be eliminated from the hybrid virus and from the vector.

Deletions may also be made in any of the late genes L1 through L5, which span mu 16.45 to 99 of the adenovirus genome. Similarly, deletions may be useful in the intermediate genes IX which maps between mu

9.8 and 11.2 and IVA<sub>2</sub> which maps between 16.1 to 11.1. Other deletions may occur in the other structural or non-structural adenovirus.

The above discussed deletions may occur individually, i.e., an adenovirus sequence for use in the present invention may contain deletions of E1 only. Alternatively, deletions of entire genes or portions effective to destroy their biological activity may occur in any combination. For example, in one exemplary hybrid vector, the adenovirus sequence may contain deletions of the E1 genes and the E3 gene, or of the E1, E2a and E3 genes, or of the E1 and E4 genes, or of E1, E2a and E4 genes, with or without deletion of E3, and so on.

The more deletions in the adenovirus sequence up to the minimum sequences identified above that characterize the hybrid virus, the larger the sequence(s) of the other below-described components to be inserted in the hybrid vector. As described above for the minimum adenovirus sequences, those gene sequences not present in the adenovirus portion of the hybrid virus must be supplied by either a packaging cell line and/or a helper adenovirus to generate the hybrid virus.

In an exemplary hybrid virus of this invention which is described below and in Example 1, the adenovirus genomic sequences present are from mu 0 to 1, mu 9 to 78.3 and mu 86 to 100 (deleted sequences eliminate the E1a and E1b genes and a portion of the E3 gene). From the foregoing information, it is expected that one of skill in the art may construct hybrid vectors and viruses containing more or less of the adenovirus gene sequence.

The portions of the adenovirus genome in the hybrid virus permit high production titers of the virus to be produced, often greater than  $1 \times 10^{13}$  pfu/ml. This is in stark contrast to the low titers ( $1 \times 10^6$  pfu/ml) that have been found for recombinant AAV.

B. The AAV Components of the Vector and Virus

Also part of the hybrid vectors and viruses of this invention are sequences of an adeno-associated virus. The AAV sequences useful in the hybrid vector are the viral sequences from which the rep and cap polypeptide encoding sequences are deleted. More specifically, the AAV sequences employed are the cis-acting 5' and 3' inverted terminal repeat (ITR) sequences [See, e.g., B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp.155-168 (1990)]. As stated above, the ITR sequences are about 143 bp in length. Substantially the entire sequences encoding the ITRs are used in the vectors, although some degree of minor modification of these sequences is expected to be permissible for this use. See, e.g., WO 93/24641, published December 9, 1993. The ability to modify these ITR sequences is within the skill of the art. For suitable techniques, see, e.g., texts such as Sambrook et al, "Molecular Cloning. A Laboratory Manual.", 2d edit., Cold Spring Harbor Laboratory, New York (1989).

The AAV ITR sequences may be obtained from any known AAV, including presently identified human AAV types. Similarly, AAVs known to infect other animals may also be employed in the vector constructs of this invention. The selection of the AAV is not anticipated to limit the following invention. A variety of AAV strains, types 1-4, are available from the American Type Culture Collection or available by request from a variety of commercial and institutional sources. In the following exemplary embodiment an AAV-2 is used for convenience.

In the hybrid vector construct, the AAV sequences are flanked by the selected adenovirus sequences discussed above. The 5' and 3' AAV ITR sequences themselves flank a selected transgene sequence

and associated regulatory elements, described below. Thus, the sequence formed by the transgene and flanking 5' and 3' AAV sequences may be inserted at any deletion site in the adenovirus sequences of the vector. For example, the AAV sequences are desirably inserted at the site of the deleted E1a/E1b genes of the adenovirus, i.e., after map unit 1. Alternatively, the AAV sequences may be inserted at an E3 deletion, E2a deletion, and so on. If only the adenovirus 5' ITR/packaging sequences and 3' ITR sequences are used in the hybrid virus, the AAV sequences are inserted between them.

C. The Transgene Component of the Hybrid Vector and Virus

The transgene sequence of the vector and recombinant virus is a nucleic acid sequence or reverse transcript thereof, heterologous to the adenovirus sequence, which encodes a polypeptide or protein of interest. The transgene is operatively linked to regulatory components in a manner which permits transgene transcription.

The composition of the transgene sequence will depend upon the use to which the resulting hybrid vector will be put. For example, one type of transgene sequence includes a reporter sequence, which upon expression produces a detectable signal. Such reporter sequences include without limitation an *E. coli* beta-galactosidase (*LacZ*) cDNA, an alkaline phosphatase gene and a green fluorescent protein gene. These sequences, when associated with regulatory elements which drive their expression, provide signals detectable by conventional means, e.g., ultraviolet wavelength absorbance, visible color change, etc.

Another type of transgene sequence includes a therapeutic gene which expresses a desired gene product in a host cell. These therapeutic genes or

nucleic acid sequences typically encode products for administration and expression in a patient *in vivo* or *ex vivo* to replace or correct an inherited or non-inherited genetic defect or treat an epigenetic disorder or disease. Such therapeutic genes which are desirable for the performance of gene therapy include, without limitation, a normal cystic fibrosis transmembrane regulator (CFTR) gene, a low density lipoprotein (LDL) gene, and a number of genes which may be readily selected by one of skill in the art. The selection of the transgene is not considered to be a limitation of this invention, as such selection is within the knowledge of those skilled in the art.

*D. Regulatory Elements of the Hybrid Vector*

In addition to the major elements identified above for the hybrid vector, i.e., the adenovirus sequences, AAV sequences and the transgene, the vector also includes conventional regulatory elements necessary to drive expression of the transgene in a cell transfected with the hybrid vector. Thus the vector contains a selected promoter which is linked to the transgene and located, with the transgene, between the AAV ITR sequences of the vector.

Selection of the promoter is a routine matter and is not a limitation of the hybrid vector itself. Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the amount of the transgene to be expressed. For example, a desirable promoter is that of the cytomegalovirus immediate early promoter/enhancer [see, e.g., Boshart et al, *Cell*, 41:521-530 (1985)]. Other desirable promoters include, without limitation, the Rous sarcoma virus LTR promoter/enhancer and the chicken  $\beta$ -actin promoter. Still other promoter/enhancer sequences may be selected by one of skill in the art.

The vectors will also desirably contain nucleic acid sequences heterologous to the adenovirus sequences including sequences providing signals required for efficient polyadenylation of the transcript and  
5 introns with functional splice donor and acceptor sites. A common poly-A sequence which is employed in the exemplary vectors of this invention is that derived from the papovavirus SV-40. The poly-A sequence generally is inserted in the vector following the transgene sequences  
10 and before the 3' AAV ITR sequence. A common intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence. A hybrid vector of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence  
15 and the transgene. Selection of these and other common vector elements are conventional and many such sequences are available [see, e.g., Sambrook et al, and references cited therein]. The DNA sequences encoding such regulatory regions are provided in the plasmid sequence  
20 of Fig. 2\* [SEQ ID NO: 1].

The combination of the transgene, promoter/enhancer, the other regulatory vector elements and the flanking 5' and 3' AAV ITRs are referred to as a "minigene" for ease of reference herein. As above  
25 stated, the minigene is located in the site of any selected adenovirus deletion in the hybrid virus. The size of this minigene depends upon the amount and number of adenovirus sequence deletions referred to above. Such a minigene may be about 8 kb in size in the exemplary  
30 virus deleted in the E1 and E3 genes, as described in the examples below. Alternatively, if only the minimum adenovirus sequences are employed in the virus, this minigene may be a size up to about 30 kb. Thus, this hybrid vector and vector permit a great deal of latitude  
35 in the selection of the various components of the

minigene, particularly the transgene, with regard to size. Provided with the teachings of this invention, the design of such a minigene can be made by resort to conventional techniques.

5                   E. Hybrid Vector Assembly and Production of Hybrid Virus

The material from which the sequences used in the hybrid vector, helper viruses, if needed, and recombinant hybrid virus (or viral particle) are derived and the various vector components and sequences employed in the construction of the hybrid vectors of this invention are obtained from commercial or academic sources based on previously published and described materials. These materials may also be obtained from an individual patient or generated and selected using standard recombinant molecular cloning techniques known and practiced by those skilled in the art. Any modification of existing nucleic acid sequences forming the vectors and viruses, including sequence deletions, insertions, and other mutations are also generated using standard techniques.

Assembly of the selected DNA sequences of the adenovirus, the AAV and the reporter genes or therapeutic genes and other vector elements into the hybrid vector and the use of the hybrid vector to produce a hybrid virus utilize conventional techniques, such as described in Example 1. Such techniques include conventional cloning techniques of cDNA such as those described in texts [Sambrook et al, cited above], use of overlapping oligonucleotide sequences of the adenovirus and AAV genomes, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence. Standard transfection and co-transfection techniques are employed, e.g.,  $\text{CaPO}_4$  transfection techniques using the complementation human embryonic

kidney (HEK) 293 cell line (a human kidney cell line containing a functional adenovirus E1a gene which provides a transacting E1a protein). Other conventional methods employed in this invention include homologous recombination of the viral genomes, plaquing of viruses in agar overlay, methods of measuring signal generation, and the like.

As described in detail in Example 1 below and with resort to Fig. 1, a unique hybrid virus of this invention is prepared which contains an E1-deleted, partially E3 deleted, adenovirus sequence associated with a single copy of a recombinant AAV having deletions of its rep and cap genes and encoding a selected reporter transgene. Briefly, this exemplary hybrid virus was designed such that the AV.CMVLacZ sequence [SEQ ID NO: 1] (a minigene containing a 5' AAV ITR, a CMV promoter, an SV-40 intron, a LacZ transgene, an SV-40 poly-A sequence and a 3' AAV ITR) was positioned in place of the adenovirus type 5 (Ad5) E1a/E1b genes, making the adenovirus vector replication defective.

Because of the limited amount of adenovirus sequence present in the hybrid vectors of this invention, including the pAV.CMVLacZ [SEQ ID NO: 1] above, a packaging cell line or a helper adenovirus or both may be necessary to provide sufficient adenovirus gene sequences necessary for a productive viral infection to generate the hybrid virus.

Helper viruses useful in this invention contain selected adenovirus gene sequences not present in the hybrid vector construct or expressed by the cell line in which the hybrid vector is transfected. Optionally, such a helper virus may contain a second reporter minigene which enables separation of the resulting hybrid virus and the helper virus upon purification. The

construction of desirable helper viruses is within the skill of the art.

As one example, if the cell line employed to produce the recombinant virus is not a packaging cell line, and the hybrid vector contains only the minimum adenovirus sequences identified above, the helper virus may be a wild type Ad virus. Thus, the helper virus supplies the necessary adenovirus early genes E1, E2a, E4 and all remaining late, intermediate, structural and non-structural genes of the adenovirus genome. However, if, in this situation, the packaging cell line is 293, which supplies the E1 proteins, the helper virus need not contain the E1 gene.

In another embodiment, when the hybrid construct is rendered replication defective by a functional deletion in E1 but contains no other deletions in Ad genes necessary for production of an infective viral particle, and the 293 cell line is employed, no helper virus is necessary for production of the hybrid virus. Additionally, all or a portion of the adenovirus delayed early gene E3 (which spans mu 76.6 to 86.2) may be eliminated from the helper virus useful in this invention because this gene product is not necessary for the formation of a functioning hybrid virus particle.

It should be noted that one of skill in the art may design other helper viruses or develop other packaging cell lines to complement the adenovirus deletions in the vector construct and enable production of the hybrid virus particle, given this information. Therefore, this invention is not limited by the use or description of any particular helper virus or packaging cell line.

Thus, as described in Figs. 1A through 1C, the circular plasmid pAd.AV.CMVLacZ [SEQ ID NO: 1] (containing the minigene and only adenovirus sequences

from map unit 0 to 1 and 9 to 16) was digested and co-transfected with a selected Ad5 helper virus (containing adenovirus sequences 9 to 78.4 and 86 to 100) into 293 cells. Thus, the packaging cell line provides the E1 proteins and the helper virus provides all necessary adenovirus gene sequences subsequent to map unit 16. Homologous recombination occurs between the helper virus and the hybrid vector, resulting in the hybrid viral particle. Growth of this hybrid viral particle in 293 cells has been closely monitored for greater than 20 rounds of amplification with no indication of genome instability. Rescue and integration of the transgene from the hybrid virus into a host cell and further modifications of the vector are described below. The resulting hybrid virus Ad.AV.CMV<sub>LacZ</sub> combines the high titer potential of adenovirus with the integrating biology associated with AAV latency.

#### G. Hybrid Virus Polycation Conjugates

Rep expression is required for rescue of the rAAV genome to occur. A preferred approach is to synthetically incorporate a plasmid permitting expression of rep into the hybrid particle. To do so, the hybrid viruses described above are further modified by resort to adenovirus-polylysine conjugate technology. See, e.g., Wu et al, J. Biol. Chem., 264:16985-16987 (1989); and K. J. Fisher and J. M. Wilson, Biochem. J., 299: 49 (April 1, 1994), incorporated herein by reference. Using this technology, a hybrid virus as described above is modified by the addition of a poly-cation sequence distributed around the capsid of the hybrid viral particle. Preferably, the poly-cation is poly-lysine, which attaches around the negatively-charged virus to form an external positive charge. A plasmid containing the AAV rep gene (or a functional portion thereof) under the control of a suitable promoter is then complexed directly

to the hybrid capsid, resulting in a single viral particle containing the hybrid virus and an AAV *rep* gene. The negatively charged plasmid DNA binds with high affinity to the positively charged polylysine.

- 5 Essentially the techniques employed in constructing this hybrid virus conjugate or trans-infection particle are as described in detail in Example 3 below.

An alternative embodiment of the hybrid vector and resulting viral particle is provided by  
10 altering the *rep* containing plasmid to also contain an AAV *cap* gene. This embodiment of the hybrid vector when in a host cell is thus able to produce a recombinant AAV particle, as discussed in more detail below.

The plasmids employed in these embodiments  
15 contain conventional plasmid sequences, which place a selected AAV sequence, i.e., *rep* and/or *cap* gene sequences, under the control of a selected promoter. In the example provided below, the exemplary plasmid is pRep78/52 [SEQ\_ID NO: 2], a trans-acting plasmid  
20 containing the AAV sequences that encode *rep* 78 kD and 52 kD proteins under the control of the AAV P5 promoter. The plasmid also contains an SV40 polyadenylation signal. The DNA sequence of this plasmid is provided in Fig. 8 [SEQ ID NO: 2].

25 In a similar manner and with resort to plasmid and vector sequences known to the art, analogous plasmids may be designed using both *rep* and *cap* genes, and different constitutive or regulated promoters, optional poly-A sequences and introns.

30 The availability of materials to make these modified hybrid vectors and viruses and the AAV *rep* and/or *cap* containing vectors and the techniques involved in the assembly of the hybrid vector and *rep* and/or *cap* containing plasmids are conventional as described above.  
35 The assembly techniques for the trans-infection particle

employ the techniques described above for the hybrid vector and the techniques of Wu et al and Fisher et al, cited above. The use of this trans-infection particle including rescue and integration of the transgene into the host cell is described below.

## II. Function of the Hybrid Virus

### A. The Hybrid Virus Infects a Target Cell

Once the hybrid virus or trans-infection particle is constructed as discussed above, it is targeted to, and taken up by, a selected target cell. The selection of the target cell also depends upon the use of the hybrid virus, i.e., whether or not the transgene is to be replicated *in vitro* for production of a recombinant AAV particle, or *ex vivo* for production into a desired cell type for redelivery into a patient, or *in vivo* for delivery to a particular cell type or tissue. Target cells may therefor be any mammalian cell (preferably a human cell). For example, in *in vivo* use, the hybrid virus can target to any cell type normally infected by adenovirus, depending upon the route of administration, i.e., it can target, without limitation, neurons, hepatocytes, epithelial cells and the like. Uptake of the hybrid virus by the cell is caused by the infective ability contributed to the vector by the adenovirus and AAV sequences.

### B. The Transgene is Rescued.

Once the hybrid virus or trans-infection particle is taken up by a cell, the AAV ITR flanked transgene must be rescued from the parental adenovirus backbone. Rescue of the transgene is dependent upon supplying the infected cell with an AAV *rep* gene. Thus, efficacy of the hybrid virus can be measured in terms of *rep* mediated rescue of rAAV from the parental adenovirus template.

The rep genes can be supplied to the hybrid virus by several methods. One embodiment for providing rep proteins in trans was demonstrated with the exemplary hybrid virus Ad.AV.CMVLacZ by transfecting into the target monolayer of cells previously infected with the hybrid vector, a liposome enveloped plasmid pRep78/52 [SEQ ID NO: 2] containing the genes encoding the AAV rep 78 kDa and 52 kDa proteins under the control of the AAV P5 promoter. Rescue and amplification of a double-stranded AAV monomer and a double-stranded AAV dimer, each containing the LacZ transgene described above, was observed in 293 cells. This is described in detail in Example 2.

The production of rep in trans can be modulated by the choice of promoter in the rep containing plasmid. If high levels of rep expression are important early for rescue of the recombinant AAV domain, a heterologous (non-adenovirus, non-AAV) promoter may be employed to drive expression of rep and eliminate the need for E1 proteins. Alternatively, the low levels of rep expression from P5 that occur in the absence of adenovirus E1 proteins may be sufficient to initiate rescue and optimal to drive integration of the recombinant AAV genome in a selected use.

More preferably for in vivo use, the AAV rep gene may also be delivered as part of the hybrid virus. One embodiment of this single particle concept is the polycation conjugated hybrid virus (see Fig. 7). Infection of this trans-infection particle is accomplished in the same manner and with regard to the same target cells as identified above. The polylysine conjugate of the hybrid virus onto which was directly complexed a plasmid that encoded the rep 78 and 52 proteins, combines all of the functional components into a single particle structure. Thus, the trans-infection

particle permits delivery of a single particle to the cell, which is considerably more desirable for therapeutic use. Similar experiments to demonstrate rescue of the transgene from the hybrid conjugate trans-  
infection particle in 293 cells and in HeLa cells are detailed in Example 4.

In another embodiment, the hybrid virus is modified by cloning the rep cDNA directly into the adenovirus genome portion of the hybrid vector. Because it is known that even residual levels of rep expression can interfere with replication of adenovirus DNA, such incorporation of rep into the hybrid vector itself is anticipated to require possible mutation of the rep genes to encode only selected domains, and the use of inducible promoters to regulate rep expression, as well as careful placement of the rep genes into the adenovirus sequences of the hybrid vector.

C. Transgene Integrates into Chromosome

Once uncoupled (rescued) from the genome of the hybrid virus, the recombinant AAV/transgene minigene seeks an integration site in the host chromatin and becomes integrated therein, providing stable expression of the accompanying transgene in the host cell. This aspect of the function of the hybrid virus is important for its use in gene therapy. The AAV/transgene minigene sequence rescued from the hybrid virus achieves provirus status in the target cell, i.e., the final event in the hybrid lifecycle (Fig. 7).

To determine whether the AAV minigene rescued from the hybrid virus achieves provirus status in a target cell, non-E1 expressing HeLa cells were infected with the hybrid vector-poly-Lysine conjugate complexed with pRep78/52 [SEQ ID NO: 2] and passaged until stable colonies of LacZ expressing cells are evident. A duplicate plate of cells was infected with the same

25

conjugate, but instead of being complexed with the pRep78/52 plasmid [SEQ ID NO: 2], carried an irrelevant plasmid. Cells that receive the rep containing hybrid particle produced a greater number of stable *LacZ* positive colonies than cells infected with the control vector. This indicates multiple rescue and integration events in cells that expressed rep proteins. Confirmation of integration is revealed by characterizing the recombinant AAV genome in the hybrid infected cells and identifying flanking chromosomal sequences (see Example 5).

### III. Use of the Hybrid Viruses and Viral Particles in Gene Therapy

The novel hybrid virus and trans-infection particles of this invention provide efficient gene transfer vehicles for somatic gene therapy. These hybrid viruses are prepared to contain a therapeutic gene in place of the *LacZ* reporter transgene illustrated in the exemplary vector. By use of the hybrid viruses and trans-infection particles containing therapeutic transgenes, these transgenes can be delivered to a patient *in vivo* or *ex vivo* to provide for integration of the desired gene into a target cell. Thus, these hybrid viruses and trans-infection particles can be employed to correct genetic deficiencies or defects. Two examples of the generation of gene transfer vehicles for the treatment of cystic fibrosis and familial hypercholesterolemia are described in Examples 6 and 7 below. One of skill in the art can generate any number of other gene transfer vehicles by including a selected transgene for the treatment of other disorders. For example, the trans-infection particles are anticipated to be particularly advantageous in *ex vivo* gene therapy

35

where transduction and proviral integration in a stem cell is desired, such as in bone marrow directed gene therapy.

The hybrid viruses and trans-infection particles of the present invention may be administered to a patient, preferably suspended in a biologically compatible solution or pharmaceutically acceptable delivery vehicle. A suitable vehicle includes sterile saline. Other aqueous and non-aqueous isotonic sterile injection solutions and aqueous and non-aqueous sterile suspensions known to be pharmaceutically acceptable carriers and well known to those of skill in the art may be employed for this purpose.

The hybrid viruses and trans-infection particles of this invention may be administered in sufficient amounts to transfect the desired cells and provide sufficient levels of integration and expression of the selected transgene to provide a therapeutic benefit without undue adverse or with medically acceptable physiological effects which can be determined by those skilled in the medical arts. Conventional and pharmaceutically acceptable routes of administration include direct delivery to the target organ, tissue or site, intranasal, intravenous, intramuscular, subcutaneous, intradermal, oral and other parental routes of administration. Routes of administration may be combined, if desired.

Dosages of the hybrid virus and/or trans-infection particle will depend primarily on factors such as the condition being treated, the selected gene, the age, weight and health of the patient, and may thus vary among patients. A therapeutically effective human dose of the hybrid viruses or trans-infection particles of the present invention is believed to be in the range of from about 20 to about 50 ml of saline solution containing

concentrations of from about  $1 \times 10^7$  to  $1 \times 10^{10}$  pfu/ml hybrid virus of the present invention. A preferred human dose is about 20 ml saline solution at the above concentrations. The dosage will be adjusted to balance the therapeutic benefit against any side effects. The levels of expression of the selected gene can be monitored to determine the selection, adjustment or frequency of dosage administration.

10 IV. High Efficiency Production of rAAV

The hybrid viruses and trans-infection particles of this invention have another desirable utility in the production of large quantities of recombinant AAV particles. Due to the complicated current methods for generating AAV, there is only a limited amount of AAV available for use in industrial, medical and academic biotechnology procedures. The vectors and viruses of the present invention provide a convenient and efficient method for generating large quantities of rAAV particles.

According to this aspect of the invention, a trans-infection particle is constructed as described above and in Example 3 and is employed to produce high levels of rAAV as detailed in Example 8, with the possible modifications described in Example 9 below. Briefly, a plasmid is generated that contains both AAV rep and cap genes under the control of a suitable plasmid and is complexed to the poly-lysine exterior of the hybrid virus as described above. This trans-infection particle is then permitted to infect a selected host cell, such as 293 cells. The presence of both rep and cap permit the formation of AAV particles in the cells and generate an AAV virus titer of about  $10^9$  virions. In contrast, current methods involving the transfection of multiple plasmids produce only about  $10^7$  virion titer.

The rAAV is isolated from the culture by selecting the LacZ-containing blue plaques and purifying them on a cesium chloride gradient.

The benefit of this procedure relates to the fact that the *cis* AAV element is encoded by the parental adenovirus genome. As a result, the *trans* plasmid is the only DNA component that is needed for complex formation. The cell is thereby loaded with significantly more copies of the *trans*-acting *rep* and *cap* sequences, resulting in improved efficiency of rescue and packaging.

Numerous comparative studies focusing on the optimal ratio and copy number of the *cis* and *trans* plasmids for AAV production indicated that there is a positive correlation between the *trans* plasmid copy number and yield of recombinant virus. As described in detail in Example 8, the yield of recombinant AV.CMV~~LacZ~~ virus was increased by 5-10 fold by using the *trans*-infection particle instead of a standard adenovirus vector.

The primary limitation associated with the production of recombinant AAV using a hybrid virus of this invention relates to difficulties that arise in distinguishing between the two viruses (i.e., adenovirus and AAV) that are produced by the cell. Using the exemplary vectors and vector components of this invention, LacZ histochemical staining could not be used to titer the yield of recombinant AV.CMV~~LacZ~~ since any contaminating Ad.AV.CMV~~LacZ~~ hybrid would contribute to the final count. Therefore, a rapid Southern blot technique for quantitating yields of recombinant AAV was incorporated. The assay that was developed enabled not only quantitation and verification of AAV production, but also demonstrated the removal of contaminating hybrid virus from purified AAV stocks.

Another method for detecting contaminating hybrid virions involves modifying the hybrid vector by inserting a small second reporter minigene (i.e., reporter gene, promoter and other expression control sequences, where desired) into the E3 region of the parental adenovirus backbone. Because this reporter is not linked to the AAV domain, contaminating hybrid virus that is present during purification can be monitored by this hybrid-specific marker. Another possible reporter gene is the nucleic acid sequence for green fluorescent protein. With this hybrid vector containing two reporter sequences, histochemical staining for alkaline phosphatase (adenovirus reporter) or  $\beta$ -galactosidase (AAV reporter) activity can be used to monitor each viral domain.

The following examples illustrate the construction and testing of the hybrid vectors of the present invention and the use thereof in the productions of recombinant AAV. These examples are illustrative only, and do not limit the scope of the present invention.

#### Example 1 - Construction of a Hybrid Virus

A first hybrid adenovirus-AAV virus was engineered by homologous recombination between DNA extracted from an adenovirus and a complementing vector according to protocols previously described [see, e.g., K. F. Kozarsky et al, J. Biol. Chem., 269:13695-13702 (1994) and references cited therein]. The following description refers to the diagram of Fig. 1.

Adenovirus DNA was extracted from CsCl purified d17001 virions, an Ad5 (serotype subgroup C) variant that carries a 3 kb deletion between mu 78.4 through 86 in the nonessential E3 region (provided by Dr. William Wold, Washington University, St. Louis, Missouri). Adenoviral

DNA was prepared for co-transfection by digestion with ClaI (adenovirus genomic bp position 917) which removes the left arm of the genome encompassing adenovirus map units 0-2.5. See lower diagram of Fig. 1B.

5           The complementing hybrid vector, pAd.AV.CMV<sub>LacZ</sub> (see Fig. 1A and Fig. 2 [SEQ ID NO: 1]) was constructed as follows:

          A parental cloning vector, pAd.BglII was designed. It contains two segments of wild-type Ad5 genome (i.e., map units 0-1 and 9-16.1) separated by a  
10       unique BglII cloning site for insertion of heterologous sequences. The missing Ad5 sequences between the two domains (adenovirus genome bp 361-3327) results in the deletion of E1a and the majority of E1b following  
15       recombination with viral DNA.

          A recombinant AAV genome (AV.CMV<sub>LacZ</sub>) was designed and inserted into the BglII site of pAd.BglII to generate the complementing plasmid. The linear arrangement of AV.CMV<sub>LacZ</sub> [SEQ ID NO: 1] (see top diagram  
20       of Fig. 1B) includes:

          (a) the 5' AAV ITR (bp 1-173) obtained by PCR using pAV2 [C. A. Laughlin et al, Gene, 23: 65-73 (1983)] as template [nucleotide numbers 365-538 of Fig. 2 [SEQ ID NO: 1]];

25       (b) a CMV immediate early enhancer/promoter [Boshart et al, Cell, 41:521-530 (1985); nucleotide numbers 563-1157 of Fig. 2 [SEQ ID NO: 1]],

          (c) an SV40 splice donor-splice acceptor (nucleotide numbers 1178-1179 of Fig. 2 [SEQ ID NO: 1]),

30       (d) *E. coli* beta-galactosidase cDNA (nucleotide numbers 1356 - 4827 of Fig. 2 [SEQ ID NO: 1]),

          (e) an SV40 polyadenylation signal (a 237 Bam HI-BclI restriction fragment containing the  
35       cleavage/poly-A signals from both the early and late

transcription units; nucleotide numbers 4839 - 5037 of Fig. 2 [SEQ ID NO: 1]) and

(f) 3'AAV ITR, obtained from pAV2 as a SnaBI-BglIII fragment (nucleotide numbers 5053 - 5221 of Fig. 2 [SEQ ID NO: 1]).

The resulting complementing hybrid vector, pAd.AV.CMV $\text{LacZ}$  (see Fig. 1A and Fig. 2 [SEQ ID NO: 1]), contained a single copy of recombinant AV.CMV $\text{LacZ}$  flanked by adenovirus coordinates 0-1 on one side and 9-16.1 on the other. Plasmid DNA was linearized using a unique NheI site immediately 5' to adenovirus map unit zero (0) (resulting in the top diagram of Fig. 1B).

Both the adenovirus substrate and the complementing vector DNAs were transfected to 293 cells [ATCC CRL1573] using a standard calcium phosphate transfection procedure [see, e.g., Sambrook et al, cited above]. The end result of homologous recombination involving sequences that map to adenovirus map units 9-16.1 is hybrid Ad.AV.CMV $\text{LacZ}$  (see Fig. 1C) in which the Ela and E1b coding regions from the dl7001 adenovirus substrate are replaced with the AV.CMV $\text{LacZ}$  from the hybrid vector.

Twenty-four hours later, the transfection cocktail was removed and the cells overlaid with 0.8% agarose containing 1x BME and 2% fetal bovine serum (FBS). Once viral plaques developed (typically 10-12 days post-transfection), plaques were initially screened for *E. coli*  $\beta$ -galactosidase ( $\text{LacZ}$ ) activity by overlaying the infected monolayer with agarose supplemented with a histochemical stain for  $\text{LacZ}$ , according to the procedure described in J. Price et al, Proc. Natl. Acad. Sci., USA, 84:156-160 (1987). Positive clones (identified by the deposit of insoluble blue dye) were isolated, subjected to three rounds of freeze (dry ice/ethanol)-thaw (37°C) and an aliquot of the suspended plaque was used to infect

a fresh monolayer of 293 cells seeded on duplicate 60mm plates.

Twenty-four hours later the cells from one set of plates were fixed and again stained for LacZ activity. Cells from the duplicate plate were harvested, suspended in 0.5 ml 10 mM Tris-Cl, pH8.0, and lysed by performing a series of three freeze (dry ice/ethanol)-thaw (37°C) cycles. Cell debris was removed by centrifugation and an aliquot of the supernatant used to measure LacZ enzyme activity.

As indicated in Fig. 3, assays for  $\beta$ -galactosidase activity which measured the absorbance at 420 nm of the beta-galactosidase blue color in successful recombinants, revealed that eight of the ten isolated, putative positive clones (D1A through D1J) expressed high levels of enzyme. Histochemical staining produced similar results.

Large-scale production and purification of recombinant virus was performed as described in Kozarsky et al, cited above, and references cited therein.

#### Example 2-- Functional Analysis of Hybrid Vector

The ability to rescue the AV.CMVLacZ sequence [SEQ ID NO: 1] from the hybrid virus represented an important feature of the hybrid vector and virus systems of Example 1. To evaluate this feature, it was necessary to provide the necessary AAV gene products in trans that direct AAV excision and amplification (i.e. rep proteins). Furthermore, this experiment was conducted in 293 cells to transcomplement the E1 deletion in the Ad.AV.CMVLacZ clones, because the adenovirus E1 gene proteins have been shown to be important for initiating the lytic phase of the AAV lifecycle.

293 cells were seeded onto 6-well 35 mm plates at a density of  $1 \times 10^6$  cells/well. Twenty-four hours

later, seeding media [DMEM/10% FBS supplemented with antibiotics] was replaced with 1.0 ml DMEM/2% FBS and infected with Ad.AV.CMVLacZ hybrid clones at an MOI of 1. Two hours later, each well was transfected with 1 µg  
5 plasmid pRep78/52 [SEQ ID NO: 2], a trans-acting plasmid that encodes the sequence encoding the AAV rep 78 kD and 52 kD proteins. The rep sequences in this construct are under the control of the AAV P5 promoter and utilize an SV40 polyadenylation signal.

10 As a positive control for AAV rescue, 293 cells seeded in a 6-well plate as above were co-transfected with a cis-acting AAV plasmid pAV.CMVLacZ and pRep78/52. pAV.CMVLacZ contained AV.CMVLacZ, the identical sequence encoded by pAd.AV.CMVLacZ [SEQ ID NO: 1] described in  
15 Example 1 cloned into the BglII site of pSP72 (Promega).

To provide the necessary adenovirus helper function for AAV rescue, cells were infected with either wild-type Ad5 virus or a first generation E1-deleted virus Ad.CMhpAP at an MOI of 5, approximately 2 hours  
20 prior to adding the transfection cocktail. Ad.CMhpAP is identical to Ad.CMVLacZ (Example 1) with the modification that the alkaline phosphatase sequence (which can be obtained from Genbank) is inserted in place of the LacZ gene.

25 Transfections were performed with Lipofectamine (Life Technologies) according to the instructions provided by the manufacturer. Thirty hours post-transfection, the cells were harvested and episomal DNA (Hirt extract) prepared as described by J. M. Wilson et  
30 al, J. Biol. Chem., 267:(16):11483-11489 (1992). Samples were resolved on a 1.2% agarose gel and electroblotted onto a nylon membrane. Blots were hybridized (Southern) with a <sup>32</sup>p random primer-labeled restriction fragment isolated from the *E. coli* LacZ cDNA.

The full spectrum of duplex molecular species that appear during a lytic AAV infection (i.e., monomeric forms of the double stranded intermediates, RFm and RFd, respectively) were evident in transfected cells infected with wild type and E1 deleted Ad. No replicative intermediates were detected when transfections were performed in the absence of helper virus.

Hirt extracts from the 293 cells infected with putative Ad.AV.CMVLacZ hybrid clones D1A and D1C revealed a single band corresponding to the viral DNA, when probed with a LacZ restriction fragment. In the presence of rep proteins 78 and 52, however, the same clones yielded a banding pattern that included not only the adenovirus DNA, but an RF monomer and dimer of AV.CMVLacZ. A single-stranded form of AV.CMVLacZ [SEQ ID NO: 1] was not evident. Two additional clones gave similar banding patterns, D1B and D1H. In all, each of the eight Ad.AV.CMVLacZ hybrids that were found in Fig. 3 to express high levels of Lac Z activity were positive for rescue of the AAV domain.

With the exception of an extra band of approximately 3.5 kb, the rescue of the AV.CMVLacZ [SEQ ID NO: 1] from the hybrid viral DNA was nearly identical to results obtained from a standard *cis* and *trans* plasmid-based approach. In these later samples, adenovirus helper function was provided by pre-infecting cells with either wild-type Ad5 or an E1-deleted recombinant virus Ad.CBhpAP (also termed H5.CBALP). The Ad.CBhpAP virus has the same sequence as the Ad.CMhpAP virus described above, except that the CMV promoter sequence is replaced by the chicken cytoplasmic  $\beta$ -actin promoter [nucleotides +1 to +275 as described in T. A. Kost et al, Nucl. Acids Res., 11(23):8287 (1983)]. The level of rescue in cells infected with WT Ad5 appeared to be greater relative to those infected with the

recombinant Ad.CPhpAP virus, likely due to the additional E1 expression provided by the wild-type genome. The relevance of including an E1 deleted adenovirus here is to document that the level of adenovirus E1 proteins expressed in 293 cells is sufficient for AAV helper function.

### Example 3 - Synthesis of Polylysine Conjugates

Another version of the viral particle of this invention is a polylysine conjugate with a rep plasmid complexed directly to the hybrid virus capsid. This conjugate permits efficient delivery of the rep expression plasmid pRep78/52 [SEQ ID NO: 2] in tandem with the hybrid virus, thereby removing the need for a separate transfection step. See, Fig. 8 for a diagrammatic outline of this construction.

Purified stocks of a large-scale expansion of Ad.AV.CMVLacZ clone D1A were modified by coupling poly-L-lysine to the virion capsid essentially as described by K. J. Fisher and J. M. Wilson, Biochem. J., 299:49-58 (1994), resulting in an Ad.AV.CMVLacZ-(Lys)<sub>n</sub> conjugate. The procedure involves three steps. First, hybrid virions are activated through primary amines on capsid proteins with the heterobifunctional water-soluble cross-linking agent, sulpho-SMCC [sulpho-(N-succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate] (Pierce). The conjugation reaction, which contained 0.5 mg (375 nmol) of sulpho-SMCC and  $6 \times 10^{12}$  A<sub>260</sub> hybrid vector particles in 3.0 ml of HBS, was incubated at 30°C for 45 minutes with constant gentle shaking. This step involved formation of a peptide bond between the active N-hydroxysuccinimide (NHS) ester of sulpho-SMCC and a free amine (e.g. lysine) contributed by an adenovirus protein sequence (capsid protein) in the recombinant virus, yielding a maleimide-activated viral particle.

Unincorporated, unreacted cross-linker was removed by gel filtration on a 1 cm x 15 cm Bio-Gel P-6DG (Bio-Rad Laboratories) column equilibrated with 50 mM Tris/HCl buffer, pH 7.0, and 150 mM NaCl. Peak  $A_{260}$  fractions containing maleimide-activated hybrid virus were combined and placed on ice.

Second, poly-L-lysine having a molecular mass of 58 kDa at 10 mg/ml in 50 mM triethanolamine buffer (pH 8.0), 150 mM NaCl and 1 mM EDTA was thiolated with 2-iminothiolane/HCl (Traut's Reagent; Pierce) to a molar ratio of 2 moles-SH/mole polylysine under  $N_2$ ; the cyclic thioimide reacts with the poly(L-lysine) primary amines resulting in a thiolated polycation. After a 45 minute incubation at room temperature the reaction was applied to a 1 cm x 15 cm Bio-Gel P6DG column equilibrated with 50 mM Tris/HCl buffer (pH 7.0), 150 mM NaCl and 2 mM EDTA to remove unincorporated Traut's Reagent.

Quantification of free thiol groups was accomplished with Ellman's reagent [5,5'-dithio-bis-(2-nitrobenzoic acid)], revealing approximately 2 mol of -SH/mol of poly(L-lysine). The coupling reaction was initiated by adding  $1 \times 10^{12}$   $A_{260}$  particles of maleimide-activated hybrid virus/mg of thiolated poly(L-lysine) and incubating the mixture on ice at 4°C for 15 hours under argon. 2-mercaptoethylamine was added at the completion of the reaction and incubation carried out at room temperature for 20 minutes to block unreacted maleimide sites.

Virus-polylysine conjugates, Ad.AV.CMVLacZ-(Lys)<sub>n</sub>, were purified away from unconjugated poly(L-lysine) by ultracentrifugation through a CsCl step gradient with an initial composition of equal volumes of 1.45 g/ml (bottom step) and 1.2 g/ml (top step) CsCl in 10 mM Tris/HCl buffer (pH 8.0). Centrifugation was at 90,000 g for 2 hours at 5°C. The final product was

dialyzed against 20 mM Hepes buffer (pH 7.8) containing 150 mM NaCl (HBS).

Complexes of Ad.AV.CMV $\text{LacZ}-(\text{Lys})_n$  with pRep78/52 plasmid DNA [SEQ ID NO: 2] were formed by adding varying quantities of Ad.AV.CMV $\text{LacZ}-(\text{Lys})_n$  in 50  $\mu\text{l}$  HBS to 0.5  $\mu\text{g}$  of pRep78/52 plasmid DNA [SEQ ID NO: 2] in 50  $\mu\text{l}$  HBS. After 30 minutes incubation at room temperature, a complex was formed of the hybrid virus Ad.AV.CMV $\text{LacZ}-(\text{Lys})_n$  associated in a single particle with the plasmid DNA containing the rep genes.

This complex, termed a trans-infection particle, was evaluated for DNA binding capacity by gel mobility shift assays performed as described in Fisher et al, cited above. This analysis revealed that the plasmid binding capacity of the purified conjugate (expressed as the number of  $A_{260}$  particles Ad.AV.CMV $\text{LacZ}-(\text{Lys})_n$  that can neutralize the charge contributed by 1  $\mu\text{g}$  plasmid DNA) was 1  $\mu\text{g}$  pRep78/52 plasmid DNA/ $6.0 \times 10^{10}$   $A_{260}$  particles Ad.AV.CMV $\text{LacZ}-(\text{Lys})_n$ .

20

#### Example 4 - Trans-Infection Protocol to Demonstrate AAV Excision and Amplification

Trans-infection complexes were prepared by mixing Ad.AV.CMV $\text{LacZ}-(\text{Lys})_n$  conjugate with pRep78/52 plasmid [SEQ ID NO: 2] and applied to 293 cells as follows. Ad.AV.CMV $\text{LacZ}-(\text{Lys})_n$  ( $6 \times 10^{10}$   $A_{260}$  particles) in 100  $\mu\text{l}$  DMEM was added dropwise to a microfuge tube containing 1  $\mu\text{g}$  plasmid DNA in 100  $\mu\text{l}$  DMEM. The mixture was gently mixed and allowed to incubate at room temperature for 10-15 minutes. The trans-infection cocktail was added to 293 cells seeded in a 35 mm 6-well as detailed above. Thirty hours later, cells were harvested and Hirt extracts prepared.

Samples were resolved on a 1.2% agarose gel and electroblotted onto a nylon membrane. Blots were hybridized (Southern) with a P-32 random primer-labeled restriction fragment isolated from the *E. coli LacZ* cDNA.

5           The Hirt extracts from 293 cells revealed a banding pattern that suggested the AV.CMV*LacZ* minigene sequence [SEQ ID NO: 1] was efficiently rescued from the hybrid conjugate. Both an RF monomer and dimer of the recombinant AV.CMV*LacZ* sequence were evident. As was  
10   observed previously, the rescue event was dependent on *rep* proteins since 293 cells that were trans-infected with a hybrid conjugate complexed with an irrelevant reporter plasmid expressing alkaline phosphatase (i.e. pCMVhpAP) revealed only Ad.AV.CMV*LacZ* DNA. This negative  
15   control for rescue was secondarily useful for demonstrating the high efficiency of gene transfer to 293 cells that was achieved with the conjugate vehicle.

          A duplicate set of 293 cells that received hybrid conjugate which was further complexed with  
20   alkaline phosphatase expression plasmid were fixed 24 hours after addition of the trans-infection cocktail and histochemically stained for *LacZ* as described in Price et al, cited above, or for alkaline phosphatase activity as  
25   described in J. H. Schreiber et al, BioTechniques, 14:818-823 (1993). Here *LacZ* was a marker for the Ad.AV.CMV*LacZ* hybrid, while alkaline phosphatase served as a reporter for the carrier plasmid. Greater than 90% of the monolayer was transduced with both  $\beta$ -galactosidase and alkaline phosphatase transgenes, showing the high  
30   efficiency of the conjugate delivery vehicle (differential staining revealed a blue color for the hybrids containing the *LacZ* marker and a purple color for the plasmids bearing the AP marker).

          Because of the important role E1 proteins have  
35   for progression of the AAV lifecycle, it was critical to

test the efficiency of the hybrid delivery system in a setting where E1 proteins are not expressed. A trans-infection experiment using the hybrid conjugate complexed with pRep78/52 [SEQ ID NO: 2] was therefore conducted in HeLa cells [ATCC CCL2] to remove the involvement of E1 proteins. The findings suggested rescue of AV.CMVLacZ occurred evidenced by the accumulation of RF monomers and dimers. Rescue from HeLa cells (which unlike the 293 cells do not contain any adenovirus E1 proteins) revealed lower levels of rescue of the transgene. The expression of *rep* from the AAV P5 promoter is upregulated by adenovirus E1 and signals the beginning of the AAV lytic cycle. In the absence of E1, *rep* expression from the P5 promoter is virtually silent which is important for maintenance of the proviral latent stages of the AAV lifecycle. It is anticipated that a promoter not dependent on E1 expression will upon substitution for P5, overcome this problem.

#### 20 Example 5 - Integration of the Transgene

A preliminary study has been performed to determine whether the AAV sequence rescued from the hybrid virus can achieve provirus status in a target cell (Fig. 7). Briefly, HeLa cells [ATCC CCL 2] were infected with the hybrid conjugate complexed with pRep78/52 [SEQ ID NO: 2] and passaged until stable colonies of *LacZ* expressing cells were evident. A duplicate plate of cells was infected with the same conjugate, but instead of being complexed with the pRep78/52 plasmid [SEQ ID NO: 2], carried an irrelevant plasmid. These findings indicated that cells that received the Rep containing hybrid particle produced a greater number of stable *LacZ* positive colonies than cells that were infected with the control virus. This could be interpreted as a reflection of multiple rescue and integration events in cells that

expressed Rep proteins. However, it is possible that an episomal form of AAV that can persist for extended periods of time was present.

To establish the occurrence of integration into the chromosome of the minigene Av.CMV $\text{LacZ}$  from the hybrid conjugate, the following experiment is performed. The Ad.AV.CMV $\text{LacZ}$ -(Lys)<sub>n</sub> conjugate carrying pRep78/52 plasmid [SEQ ID NO: 2] is used to infect HeLa cells [ATCC CRL2] (primary fibroblasts may also be used). The infected cells are passaged for several generations. The cells are grown to confluency, split and allowed to grow to confluency again, split again and this cycle repeated as desired. This permits sufficient time for uptake, expression, replication and integration to occur. See Fig. 7.

To verify that the recombinant AAV sequence that was rescued from the hybrid genome (step III of Fig. 7) has integrated into a chromosome of the host cell (step IV of Fig. 7), cells are separated by a Fluorescence Activated Cell Sorter (FACS). By this technique, those cells containing a stable integrated copy of the recombinant AV.CMV $\text{LacZ}$  minigene are separated based on the presence of the  $\beta$ -galactosidase reporter. These cells are tagged with fluorescein-labeled antibodies that recognize the  $\beta$ -Gal protein, and are then separated from non-transduced cells (i.e. those that did not receive a copy of the AAV minigene) by FACS.

DNA is isolated from this purified population of cells and used to construct a genomic library which is screened for individual clones and the sequence verified. If integration occurs, it is documented directly by sequence analysis.

Example 6 - Gene Transfer Vehicle for Cystic Fibrosis

An adenovirus-AAV-CFTR virus constructed by modifying the hybrid Ad.AV.CMVLacZ virus described in Example 1 to contain the cystic fibrosis transmembrane regulator (CFTR) gene [J.R. Riordan et al, Science, 245:1066-1073 (1989)] in place of the lacZ gene, using known techniques. One suitable method involves producing a new vector using the techniques described in Example 1. In this new vector the LacZ minigene is replaced with the CFTR minigene. For performance of this method vectors bearing the CFTR gene have been previously described and can be readily constructed. This new or reconstructed vector is used to generate a new virus through homologous recombination as described above. The resulting hybrid virus is termed hybrid Ad.AV.CMVCFTR. It has the sequence of Fig. 2 [SEQ ID NO: 1], except that the LacZ gene is replaced with CFTR. Alternatively, the LacZ gene can be removed from the Ad.AV.CMVLacZ vector of Example 1 and replaced with the CFTR gene using known techniques.

This virus (or an analogous hybrid virus with a different promoter, regulatory regions, etc.) is useful in gene therapy alone, or preferably, in the form of a conjugate prepared as described in Example 4.

Treatment of cystic fibrosis, utilizing the viruses provided above, is particularly suited for in vivo, lung-directed, gene therapy. Airway epithelial cells are the most desirable targets for gene transfer because the pulmonary complications of CF are usually its most morbid and life-limiting. Thus, the hybrid vector of the invention, containing the CFTR gene, is delivered directly into the airway, e.g. by formulating the hybrid virus above, into a preparation which can be inhaled. For example, the hybrid virus or conjugate of the invention containing the CFTR gene, is suspended in 0.25

molar sodium chloride. The virus or conjugate is taken up by respiratory airway cells and the gene is expressed.

Alternatively, the hybrid viruses or conjugates of the invention may be delivered by other suitable means, including site-directed injection of the virus bearing the CFTR gene. In the case of CFTR gene delivery, preferred solutions for bronchial instillation are sterile saline solutions containing in the range of from about  $1 \times 10^7$  to  $1 \times 10^{10}$  pfu/ml, more particularly, in the range of from about  $1 \times 10^8$  to  $1 \times 10^9$  pfu/ml of the recombinant hybrid virus of the present invention.

Other suitable methods for the treatment of cystic fibrosis by use of gene therapy recombinant viruses of this invention may be obtained from the art discussions of other types of gene therapy vehicles for CF. See, for example, U.S. Patent No. 5,240,846, incorporated by reference herein.

#### Example 7 - Gene Transfer Vehicle for Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is an autosomal dominant disorder caused by abnormalities (deficiencies) in the function or expression of LDL receptors. [M.S. Brown and J.L. Goldstein, Science, 232(4746):34-37 (1986); J.L. Goldstein and M.S. Brown, "Familial hypercholesterolemia" in Metabolic Basis of Inherited Disease, ed. C.R. Scriver et al, McGraw Hill, New York, pp1215-1250 (1989).] Patients who inherit one abnormal allele have moderate elevations in plasma LDL and suffer premature life-threatening coronary artery disease (CAD). Homozygous patients have severe hypercholesterolemia and life-threatening CAD in childhood.

A hybrid adenovirus-AAV-LDL virus of the invention is constructed by replacing the lacZ gene in the hybrid Ad.AV.CMVlacZ virus of Example 1 with an LDL receptor gene [T. Yamamoto et al, Cell, 39:27-38 (1984)]  
5 using known techniques and as described analogously for CF in the preceding example. Vectors bearing the LDL receptor gene can be readily constructed according to this invention. The resulting hybrid vector is termed pAd.AV.CMVLDL.

10 This plasmid or its recombinant virus is useful in gene therapy of FH alone, or preferably, in the form of a viral conjugate prepared as described in Example 4 to substitute a normal LDL gene for the abnormal allele responsible for the gene.

15 A. Ex Vivo Gene Therapy

Ex vivo gene therapy can be performed by harvesting and establishing a primary culture of hepatocytes from a patient. Known techniques may be used to isolate and transduce the hepatocytes with the above  
20 vector(s) bearing the LDL receptor gene(s). For example, techniques of collagenase perfusion developed for rabbit liver can be adapted for human tissue and used in transduction. Following transduction, the hepatocytes are removed from the tissue culture plates and reinfused  
25 into the patient using known techniques, e.g. via a catheter placed into the inferior mesenteric vein.

B. In Vivo Gene Therapy

Desirably, the in vivo approach to gene therapy, e.g. liver-directed, involves the use of the  
30 hybrid viruses and viral conjugates described above. A preferred treatment involves infusing a trans-infection particle of the invention containing LDL into the peripheral circulation of the patient. The patient is then evaluated for change in serum lipids and liver  
35 tissues.

The hybrid virus or viral conjugate can be used to infect hepatocytes *in vivo* by direct injection into a peripheral or portal vein ( $10^7$ - $10^8$  pfu/kg) or retrograde into the biliary tract (same dose). This effects gene transfer into the majority of hepatocytes.

Treatments are repeated as necessary, e.g. weekly. Administration of a dose of virus equivalent to an MOI of approximately 20 (i.e. 20 pfu/hepatocyte) is anticipated to lead to high level gene expression in the majority of hepatocytes.

#### Example 8 - Efficient Production of Recombinant AAV using A Hybrid Virus/Conjugate

The following experiment demonstrated that the AAV genome that was rescued from the Ad.AV.CMVLacZ hybrid virus could be packaged into an AAV capsid, provided the cap open reading frame was supplied in trans. Thus the viruses of this invention are useful in a production method for recombinant AAV which overcomes the prior art complications that surround the high titer production of recombinant AAV.

##### A. Trans-Infection Protocol for the Production of rAAV

A trans-infection complex was formed composed of the Ad.AV.CMVLacZ-(Lys)<sub>n</sub> conjugate described above and a transcomplementing plasmid pAdAAV, which is described in detail in R. J. Samulski et al, J. Virol., 63(9):3822-3828 (1989)]. Briefly, plasmid pAdAAV encodes the entire rep and cap open reading frames in the absence of AAV ITRs, and has been shown to provide the necessary AAV helper functions for replication and packaging of recombinant AAV sequences.

Ad.AV.CMVLacZ-(Lys)<sub>n</sub> conjugate ( $4.5 \times 10^{13}$  A<sub>260</sub> particles) in 75 ml DMEM was added dropwise with constant gentle swirling in 25 ml DMEM containing 750 µg

pAdAAV helper plasmid and incubated at room temperature for 10-15 minutes. The complex was diluted with 450 ml DMEM supplemented with 2% FBS and 20 ml aliquots were added to monolayers of 293 cells seeded on 150 mm plates.

5. Forty hours post trans-infection, cells were harvested, suspended in 12 ml 10 mM Tris-Cl (pH 8.0), and stored at -80°C.

Because the anticipated outcome was the production of hybrid virus Ad.AV.CMV $\text{LacZ}$  and a recombinant AAV virion (AV.CMV $\text{LacZ}$ ), both of which carry a functional  $\text{LacZ}$  minigene, it was not possible to use detection of  $\text{LacZ}$  activity as an indicator of AV.CMV $\text{LacZ}$  production. A novel molecular approach was developed that could be performed in one day and permitted identification of the packaged viral DNAs.

#### B. Purification of rAAV

Briefly, frozen cell suspensions were subjected to three rounds of freeze-thaw cycles to release recombinant AV.CMV $\text{LacZ}$  and hybrid Ad.AV.CMV $\text{LacZ}$ . On completion of the final thaw, bovine pancreatic DNase (2000 units) and ribonuclease (0.2 mg/ml final concentration) was added and the extract incubated at 37°C for 30 minutes. Cell debris was removed by centrifugation (5000xg for 10 minutes) and the clarified supernatant (15 ml) applied to a 22.5 ml step gradient composed of equal volumes of CsCl at 1.2 g/ml, 1.36 g/ml, and 1.45 g/ml 10mM Tris-Cl, pH8.0. Viral particles were banded at 25,000 rpm in a Beckman SW-28 rotor for 8 hours at 4°C. One ml fractions were collected from the bottom of the tube.

The fractions retrieved from the CsCl gradient of partially purified virus are then digested to release viral DNA from virion capsids as follows. A 5.0 $\mu$ l sample of each fraction was transferred to a microfuge tube containing 20  $\mu$ l capsid digestion buffer

46

(50mM Tris-Cl, pH8.0, 1.0mM EDTA, pH8.0, 0.5% SDS, and 1.0 mg/ml Proteinase K). The reaction was incubated at 50°C for 1 hour, allowed to cool to room temperature, diluted with 10 µl milli-Q water, and agarose gel loading dye added.

These fractions are then analyzed by Southern blotting. Samples were resolved on a 1.2% agarose gel, electroblotted onto a nylon membrane. A <sup>32</sup>P labeled LacZ restriction fragment which was common to both vectors was used as a hybridization probe to locate the migration of viral DNA through the agarose gel. Viral bands were quantitated on a Molecular Dynamics Phosphorimager.

A sample of the extract before CsCl banding was also tested and revealed both hybrid Ad.AV.CMVlacZ DNA and double-stranded RF forms (monomers and dimers) of the rescued AV.CMVlacZ sequence [SEQ ID NO: 1]. A single-stranded monomer of AV.CMVlacZ appeared to be present in the crude extract; however, it was not until the virions were concentrated by buoyant density ultracentrifugation that the single-stranded genome became clearly evident. The single-stranded recombinant genome of the virus was distributed over a range of CsCl densities and revealed a biphasic banding pattern. The two peaks of single-stranded rAAV genome occurred at densities of 1.41 and 1.45 g/ml CsCl, consistent with the reported buoyant densities of wild-type AAV in CsCl [L. M. de la Maza et al, *J. Virol.*, 33:1129-1137 (1980)]. Analysis of the fractions corresponding to the two vector forms revealed the rAAV-1.41 species was several orders of magnitude more active for lacZ transduction than the denser rAAV-1.45 g/ml variant. To avoid confusion with contaminating Ad.AAV, samples were heat inactivated (60°C for 30 min) before being added to indicator HeLa cells.

35

The peak fractions of rAAV-1.41 were combined and purified by equilibrium sedimentation in CsCl to eliminate residual adenovirus particles and concentrate rAAV virions. On the final round of  
5 ultracentrifugation, a faint but clearly visible opalescent band was observed in the middle of the gradient tube. Fractions that surrounded the band were evaluated for density, absorbance at 260 nm, and lacZ transducing particles. As the band eluted from the  
10 gradient tube, a well defined peak of 260 nm absorbing material was recorded, with a maximal absorbance occurring at a density of 1.40 g/ml CsCl. Analysis for lacZ transducing particles on HeLa cells revealed a peak  
15 results indicate rAAV was produced from the hybrid Ad.AAV virus. Furthermore, the titers achieved using the hybrid virus were 5-10 fold elevated compared to more conventional recombinant AAV production schemes (i.e., transfections with cis- and trans-acting plasmids). This  
20 represents a significant improvement in rAAV production and indicates that the hybrid is useful for large-scale rAAV production.

All references recited above are incorporated herein by reference. Numerous modifications and  
25 variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the compositions and processes of the present invention, such as those modifications permitting  
30 optimal use of the hybrid viruses as gene therapy vehicles or production vehicles for recombinant AAV production, are believed to be encompassed in the scope of the claims appended hereto.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Trustees of the University of Pennsylvania  
Wilson, James M.  
Kelley, William M.  
Fisher, Krishna J.
- (ii) TITLE OF INVENTION: Hybrid Adenovirus-AAV Vector and  
Methods of Use Thereof
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Howson and Howson
  - (B) STREET: Spring House Corporate Cntr, PO Box 457
  - (C) CITY: Spring House
  - (D) STATE: Pennsylvania
  - (E) COUNTRY: USA
  - (F) ZIP: 19477
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 08/331,384
  - (B) FILING DATE: 28-OCT-1994
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Bak, Mary E.
  - (B) REGISTRATION NUMBER: 31,215
  - (C) REFERENCE/DOCKET NUMBER: GNVPN.007PCT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 215-540-9200
  - (B) TELEFAX: 215-540-5818

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10398 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAATTCGCTA GCATCATCAA TAATATACCT TATTTTGGAT TGAAGCCAAT	50
ATGATAATGA GGGGGTGGAG TTTGTGACGT GGC GCGGGGC GTGGGAACGG	100
GGCGGGTGAC GTAGTAGTGT GGC GGAAGTG TGATGTTGCA AGTGTGGCGG	150
AACACATGTA AGCGACGGAT GTGGCAAAAG TGACGTTTTT GGTGTGCGCC	200
GGTGTACACA GGAAGTGACA ATTTTCGCGC GTTTTTAGGC GGATGTTGTA	250
GTAAATTTGG GCGTAACCGA GTAAGATTTG GCCATTTTCG CGGGAAACT	300
GAATAAGAGG AAGTGAAATC TGAATAATTT TGTGTTACTC ATAGCGCGTA	350
ATATTTGTCT AGGGAGATCT GCTGCGCGCT CGCTCGCTCA CTGAGGCCGC	400
CCGGGCAAAG CCCGGGCGTC GGGCGACCTT TGGTCGCCCC GCCTCAGTGA	450
GCGAGCGAGC GCGCAGAGAG GGAGTGGCCA ACTCCATCAC TAGGGGTTCC	500
TTGTAGTTAA TGATTAACCC GCCATGCTAC TTATCTACAA TTCGAGCTTG	550
CATGCCTGCA GGTCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA	600
CCGCCCCAAG ACCCCCGCCC ATTGACGTCA ATAATGACGT ATGTTCCCAT	650
AGTAACGCCA ATAGGGACTT TCCATTGACG TCAATGGGTG GAGTATTTAC	700
GGTAAACTGC CCACTTGGCA GTACATCAAG TGTATCATAT GCCAAGTACG	750
CCCCCTATTG ACGTCAATGA CGGTAAATGG CCCGCCTGGC ATTATGCCCA	800
GTACATGACC TTATGGGACT TTCCTACTTG GCAGTACATC TACGTATTAG	850
TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGGCGT	900
GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT	950
CAATGGGAGT TTGTTTTGGC ACCAAAATCA ACGGGACTTT CCAAATGTC	1000

GTAACAACTC	CGCCCCATTG	ACGCAAATGG	GCGGTAGGCG	TGTACGGTGG	1050
GAGGTCTATA	TAAGCAGAGC	TCGTTTAGTG	AACCGTCAGA	TCGCCTGGAG	1100
ACGCCATCCA	CGCTGTTTTG	ACCTCCATAG	AAGACACCGG	GACCGATCCA	1150
GCCTCCGGAC	TCTAGAGGAT	CCGGTACTCG	AGGAACTGAA	AAACCAGAAA	1200
GTTAACTGGT	AAGTTTAGTC	TTTTTGCTCT	TTATTTTCAGG	TCCCGGATCC	1250
GGTGGTGGTG	CAAATCAAAG	AACTGCTCCT	CAGTGGATGT	TGCCTTTACT	1300
TCTAGGCCTG	TACGGAAGTG	TTACTTCTGC	TCTAAAAGCT	GCGGAATTGT	1350
ACCCGCGGCC	GCAATTCCCG	GGGATCGAAA	GAGCCTGCTA	AAGCAAAAAA	1400
GAAGTCACCA	TGTCGTTTAC	TTTGACCAAC	AAGAACGTGA	TTTTCGTTGC	1450
CGGTCTGGGA	GGCATTGGTC	TGGACACCAG	CAAGGAGCTG	CTCAAGCGCG	1500
ATCCCGTCGT	TTTACAACGT	CGTGACTGGG	AAAACCCTGG	CGTTACCCAA	1550
CTTAATCGCC	TTGCAGCACA	TCCCCCTTTC	GCCAGCTGGC	GTAATAGCGA	1600
AGAGGCCCGC	ACCGATCGCC	CTTCCCAACA	GTTGCGCAGC	CTGAATGGCG	1650
AATGGCGCTT	TGCCTGGTTT	CCGGCACCAG	AAGCGGTGCC	GGAAAGCTGG	1700
CTGGAGTGCG	ATCTTCCTGA	GGCCGATACT	GTCGTCGTCC	CCTCAAACCTG	1750
GCAGATGCAC	GGTTACGATG	CGCCCCATCTA	CACCAACGTA	ACCTATCCCA	1800
TTACGGTCAA	TCCGCCGTTT	GTTCCCACGG	AGAATCCGAC	GGGTTGTTAC	1850
TCGCTCACAT	TTAATGTTGA	TGAAAGCTGG	CTACAGGAAG	GCCAGACGCG	1900
AATTATTTTT	GATGGCGTTA	ACTCGGCGTT	TCATCTGTGG	TGCAACGGGC	1950
GCTGGGTCCG	TTACGGCCAG	GACAGTCGTT	TGCCGTCTGA	ATTTGACCTG	2000
AGCGCATTTT	TACGCGCCGG	AGAAAACCGC	CTCGCGGTGA	TGGTGCTGCG	2050
TTGGAGTGAC	GGCAGTTATC	TGGAAGATCA	GGATATGTGG	CGGATGAGCG	2100
GCATTTTCCG	TGACGTCTCG	TTGCTGCATA	AACCGACTAC	ACAAATCAGC	2150
GATTTCCATG	TTGCCACTCG	CTTTAATGAT	GATTTTCAGCC	GCGCTGTACT	2200
GGAGGCTGAA	GTTCAGATGT	GCGGCGAGTT	GCGTGACTAC	CTACGGGTAA	2250
CAGTTTCTTT	ATGGCAGGGT	GAAACGCAGG	TCGCCAGCGG	CACCGCGCCT	2300

TTCGGCGGTG	AAATTATCGA	TGAGCGTGGT	GGTTATGCCG	ATCGCGTCAC	2350
ACTACGTCTG	AACGTCGAAA	ACCCGAAACT	GTGGAGCGCC	GAAATCCCGA	2400
ATCTCTATCG	TGCGGTGGTT	GAACTGCACA	CCGCCGACGG	CACGCTGATT	2450
GAAGCAGAAG	CCTGCGATGT	CGGTTTCCGC	GAGJTGCGGA	TTGAAAATGG	2500
TCTGCTGCTG	CTGAACGGCA	AGCCGTTGCT	GATTCGAGGC	GTTAACCGTC	2550
ACGAGCATCA	TCCTCTGCAT	GGTCAGGTCA	TGGATGAGCA	GACGATGGTG	2600
CAGGATATCC	TGCTGATGAA	GCAGAACAAC	TTTAACGCCG	TGCGCTGTTC	2650
GCATTATCCG	AACCATCCGC	TGTGGTACAC	GCTGTGCGAC	CGCTACGGCC	2700
TGTATGTGGT	GGATGAAGCC	AATATTGAAA	CCCACGGCAT	GGTGCCAATG	2750
AATCGTCTGA	CCGATGATCC	GCGCTGGCTA	CCGGCGATGA	GCGAACGCGT	2800
AACGCGAATG	GTGCAGCGCG	ATCGTAATCA	CCCGAGTGTG	ATCATCTGGT	2850
CGCTGGGGAA	TGAATCAGGC	CACGGCGCTA	ATCACGACGC	GCTGTATCGC	2900
TGGATCAAAT	CTGTCGATCC	TTCCCGCCCG	GTGCAGTATG	AAGGCGGCGG	2950
AGCCGACACC	ACGGCCACCG	ATATTATTTG	CCCGATGTAC	GCGCGCGTGG	3000
ATGAAGACCA	GCCCTTCCCG	GCTGTGCCGA	AATGGTCCAT	CAAAAAATGG	3050
CTTTCGCTAC	CTGGAGAGAC	GCGCCCGCTG	ATCCTTTGCG	AATACGCCCA	3100
CGCGATGGGT	AACAGTCTTG	GCGGTTTCGC	TAAATACTGG	CAGGCGTTTC	3150
GTCAGTATCC	CCGTTTACAG	GGCGGCTTCG	TCTGGGACTG	GGTGGATCAG	3200
TCGCTGATTA	AATATGATGA	AAACGGCAAC	CCGTGGTCGG	CTTACGGCGG	3250
TGATTTTGGC	GATACGCCGA	ACGATCGCCA	GTTCTGTATG	AACGGTCTGG	3300
TCTTTGCCGA	CCGCACGCCG	CATCCAGCGC	TGACGGAAGC	AAAACACCAG	3350
CAGCAGTTTT	TCCAGTTCCG	TTTATCCGGG	CAAACCATCG	AAGTGACCAG	3400
CGAATACCTG	TTCCGTCATA	GCGATAACGA	GCTCCTGCAC	TGGATGGTGG	3450
CGCTGGATGG	TAAGCCGCTG	GCAAGCGGTG	AAGTGCCTCT	GGATGTCGCT	3500
CCACAAGGTA	AACAGTTGAT	TGAACTGCCT	GAACTACCGC	AGCCGGAGAG	3550
CGCCGGGCAA	CTCTGGCTCA	CAGTACGCGT	AGTGCAACCG	AACGCGACCG	3600

CATGGTCAGA	AGCCGGGCAC	ATCAGCGCCT	GGCAGCAGTG	GCGTCTGGCG	3650
GAAAACCTCA	GTGTGACGCT	CCCCGCCGCG	TCCCACGCCA	TCCCGCATCT	3700
GACCACCAGC	GAAATGGATT	TTTGCATCGA	GCTGGGTAAT	AAGCGTTGGC	3750
AATTTAACCG	CCAGTCAGGC	TTTCTTTCAC	AGATLTGGAT	TGGCGATAAA	3800
AAACAACCTG	TGACGCCGCT	GCGCGATCAG	TTCACCCGTG	CACCGCTGGA	3850
TAACGACATT	GGCGTAAGTG	AAGCGACCCG	CATTGACCCT	AACGCCTGGG	3900
TCGAACGCTG	GAAGGCGGCG	GGCCATTACC	AGGCCGAAGC	AGCGTTGTTG	3950
CAGTGCACGG	CAGATACACT	TGCTGATGCG	GTGCTGATTA	CGACCGCTCA	4000
CGCGTGGCAG	CATEAGGGGA	AAACCTTATT	TATCAGCCGG	AAAACCTACC	4050
GGATTGATGG	TAGTGGTCAA	ATGGCGATTA	CCGTTGATGT	TGAAGTGGCG	4100
AGCGATACAC	CGCATCCGGC	GCGGATTGGC	CTGAACTGCC	AGCTGGCGCA	4150
GGTAGCAGAG	CGGGTAAACT	GGCTCGGATT	AGGGCCGCAA	GAAAACTATC	4200
CCGACCGCCT	TACTGCCGCC	TGTTTTGACC	GCTGGGATCT	GCCATTGTCA	4250
GACATGTATA	CCCCGTACGT	CTTCCCAGC	GAAAACGGTC	TGCGCTGCGG	4300
GACGCGCGAA	TTGAATTATG	GCCCACACCA	GTGGCGCGGC	GACTTCCAGT	4350
TCAACATCAG	CCGCTACAGT	CAACAGCAAC	TGATGGAAAC	CAGCCATCGC	4400
CATCTGCTGC	ACGEGGAAGA	AGGCACATGG	CTGAATATCG	ACGGTTTCCA	4450
TATGGGGATT	GGTGCGGACG	ACTCCTGGAG	CCCGTCAGTA	TCGGCGGAAT	4500
TACAGCTGAG	CGCCGGTCGC	TACCATTACC	AGTTGGTCTG	GTGTCAAAAA	4550
TAATAATAAC	CGGGCAGGCC	ATGTCTGCCC	GTATTTTCGCG	TAAGGAAATC	4600
CATTATGTAC	TATTTAAAAA	ACACAACTT	TTGGATGTTC	GGTTTATTCT	4650
TTTTCTTTTA	CTTTTTTATC	ATGGGAGCCT	ACTTCCCGTT	TTTCCCAGTT	4700
TGGCTACATG	ACATCAACCA	TATCAGCAAA	AGTGATACGG	GTATTATTTT	4750
TGCCGCTATT	TCTCTGTTCT	CGCTATTATT	CCAACCGCTG	TTTGGTCTGC	4800
TTTCTGACAA	ACTCGGCCTC	GACTCTAGGC	GGCCGCGGGG	ATCCAGACAT	4850
GATAAGATAC	ATTGATGAGT	TTGGACAAAC	CACAACTAGA	ATGCAGTGAA	4900

AAAAATGCTT	TATTTGTGAA	ATTTGTGATG	CTATTGCTTT	ATTTGTAACC	4950
ATTATAAGCT	GCAATAAACA	AGTTAACAAC	AACAATTGCA	TTCATTTTAT	5000
GTTTCAGGTT	CAGGGGGAGG	TGTGGGAGGT	TTTTTCGGAT	CCTCTAGAGT	5050
CGAGTAGATA	AGTAGCATGG	CGGGTTAATC	ATTA AACTACA	AGGAACCCCT	5100
AGTGATGGAG	TTGGCCACTC	CCTCTCTGCG	CGCTCGCTCG	CTCACTGAGG	5150
CCGGGCGACC	AAAGGTCGCC	CGACGCCCCG	GCTTTGCCCC	GGCGGCCTCA	5200
GTGAGCGAGC	GAGCGCGCAG	CAGATCTGGA	AGGTGCTGAG	GTACGATGAG	5250
ACCCGCACCA	GGTGCAGACC	CTGCGAGTGT	GGCGGTAAAC	ATATTAGGAA	5300
CCAGCCTGTG	ATGCTGGATG	TGACCGAGGA	GCTGAGGCC	GATCACTTGG	5350
TGCTGGCCTG	CACCCGCGCT	GAGTTTGGCT	CTAGCGATGA	AGATACAGAT	5400
TGAGGTACTG	AAATGTGTGG	GCGTGGCTTA	AGGGTGGGAA	AGAATATATA	5450
AGGTGGGGGT	CTTATGTAGT	TTTGTATCTG	TTTTGCAGCA	GCCGCCGCCG	5500
CCATGAGCAC	CAACTCGTTT	GATGGAAGCA	TTGTGAGCTC	ATATTTGACA	5550
ACGCGCATGC	CCCCATGGGC	CGGGGTGCGT	CAGAATGTGA	TGGGCTCCAG	5600
CATTGATGGT	CGCCCCGTCC	TGCCCGCAAA	CTCTACTACC	TTGACCTACG	5650
AGACCGTGTC	TGGAACGCCG	TTGGAGACTG	CAGCCTCCGC	CGCCGCTTCA	5700
GCCGCTGCAG	CCACCGCCCC	CGGGATTGTG	ACTGACTTTG	CTTTCCTGAG	5750
CCCGCTTGCA	AGCAGTGCAG	CTTCCCGTTC	ATCCGCCCCG	GATGACAAGT	5800
TGACGGCTCT	TTTGGCACAA	TTGGATTCTT	TGACCCGGGA	ACTTAATGTC	5850
GTTTCTCAGC	AGCTGTTGGA	TCTGCGCCAG	CAGGTTTCTG	CCCTGAAGGC	5900
TTCTCTCCCT	CCCAATGCGG	TTTAAACAT	AAATAAAAAA	CCAGACTCTG	5950
TTTGGAATTTG	GATCAAGCAA	GTGTCTTGCT	GTCTTTATTT	AGGGGTTTTG	6000
CGCGCGCGGT	AGGCCCCGGA	CCAGCGGTCT	CGGTCGTTGA	GGGTCCTGTG	6050
TATTTTTTCC	AGGACGTGGT	AAAGGTGACT	CTGGATGTTT	AGATACATGG	6100
GCATAAGCCC	GTCTCTGGGG	TGGAGGTAGC	ACCACTGCAG	AGCTTCATGC	6150
TGCGGGGTGG	TGTTGTAGAT	GATCCAGTCG	TAGCAGGAGC	GCTGGGCGTG	6200

GTGCCTAAAA	ATGTCTTTCA	CTAGCAAGCT	GATTGCCAGG	GGCAGGCCCT	6250
TGGTGTAAGT	GTTTACAAAG	CGGTTAAGCT	GGGATGGGTG	CATACGTGGG	6300
GATATGAGAT	GCATCTTGGA	CTGTATTTTT	AGGTTGGCTA	TGTTCCAGC	6350
CATATCCCTC	CGGGGATTCA	TGTTGTGCAG	AACCACCAGC	ACAGTGTATC	6400
CGGTGCACTT	GGGAAATTTG	TCATGTAGCT	TAGAAGGAAA	TGCGTGGAAG	6450
AACTTGAGAG	CGCCCTTGTG	ACCTCCAAGA	TMTTCCATGC	ATTCGTCCAT	6500
AATGATGGCA	ATGGGCCCAC	GGGCGGCGGC	CTGGGCGAAG	ATATTTCTGG	6550
GATCACTAAC	GTCATAGTTG	TGTTCCAGGA	TGAGATCGTC	ATAGGCCATT	6600
TTTACAAAGC	GCGGGCGGAG	GGTGCCAGAC	TGCGGTATAA	TGTTTCCATC	6650
CGGCCCAGGG	GCGTAGTTAC	CCTCACAGAT	TTGCATTTCC	CACGCTTTGA	6700
GTTCAGATGG	GGGGATCATG	TCTACCTGCG	GGGCGATGAA	GAAAACGGTT	6750
TCCGGGGTAG	GGGAGATCAG	CTGGGAAGAA	AGCAGGTTCC	TGAGCAGCTG	6800
CGACTTACCG	CAGCCGGTGG	GCCCGTAAAT	CACACCTATT	ACCGGGTGCA	6850
ACTGGTAGTT	AAGAGAGCTG	CAGCTGCCGT	CATCCCTGAG	CAGGGGGGCC	6900
ACTTCGTTAA	GCATGTCCCT	GACTCGCATG	TTTTCCCTGA	CCAAATCCGC	6950
CAGAAGGCGC	TCGCCGCCCA	GCGATAGCAG	TTCTTGCAAG	GAAGCAAAGT	7000
TTTTCAACGG	TTTGAGACCG	TCCGCCGTAG	GCATGCTTTT	GAGCGTTTGA	7050
CCAAGCAGTT	CCAGGCGGTC	CCACAGCTCG	GTCACCTGCT	CTACGGCATC	7100
TCGATCCAGC	ATATCTCCTC	GTTTCGCGGG	TTGGGGCGGC	TTTCGCTGTA	7150
CGGCAGTAGT	CGGTGCTCGT	CCAGACGGGC	CAGGGTCATG	TCTTTCCACG	7200
GGCGCAGGGT	CCTCGTCAGC	GTAGTCTGGG	TCACGGTGAA	GGGGTGCGCT	7250
CCGGGCTGCG	CGCTGGCCAG	GGTGCGCTTG	AGGCTGGTCC	TGCTGGTGCT	7300
GAAGCGCTGC	CGGTCTTCGC	CCTGCGCGTC	GGCCAGGTAG	CATTTGACCA	7350
TGGTGTCATA	GTCCAGCCCC	TCCGCGGCGT	GGCCCTTGGC	GCGCAGCTTG	7400
CCCTTGAGAG	AGGCGCCGCA	CGAGGGGCAG	TGCAGACTTT	TGAGGGCGTA	7450
GAGCTTGGGC	GCGAGAAATA	CCGATTCCGG	GGAGTAGGCA	TCCGCGCCGC	7500

AGGCCCCGCA	GACGGTCTCG	CATTCCACGA	GCCAGGTGAG	CTCTGGCCGT	7550
TCGGGGTCAA	AAACCAGGTT	TCCCCCATGC	TTTTTGATGC	GTTTCTTACC	7600
TCTGGTTTCC	ATGAGCCGGT	GTCCACGCTC	GGTGACGAAA	AGGCTGTCCG	7650
TGTCCCCGTA	TACAGACTTG	AGAGGCCTGT	CCTCGACCGA	TGCCCTTGAG	7700
AGCCTTCAAC	CCAGTCAGCT	CCTTCCGGTG	GGCGCGGGGC	ATGACTATCG	7750
TCGCCGCACT	TATGACTGTC	TTCTTTATCA	TGCAACTCGT	AGGACAGGTG	7800
CCGGCAGCGC	TCTGGGTCAT	TTTCGGCGAG	GACCGCTTTC	GCTGGAGCGC	7850
GACGATGATC	GGCCTGTGCG	TTGCGGTATT	CGGAATCTTG	CACGCCCTCG	7900
CTCAAGCCTT	CGTCACTGGT	CCCGCCACCA	AACGTTTCGG	CGAGAAGCAG	7950
GCCATTATCG	CCGGCATGGC	GGCCGACGCG	CTGGGCTACG	TCTTGCTGGC	8000
GTTGCGGACG	CGAGGCTGGA	TGGCCTTCCC	CATTATGATT	CTTCTCGCTT	8050
CCGGCGGCAT	CGGGATGCCC	GCGTTGCAGG	CCATGCTGTC	CAGGCAGGTA	8100
GATGACGACC	ATCAGGGACA	GCTTCAAGGA	TCGCTCGCGG	CTCTTACCAG	8150
CCTAACTTCG	ATCACTGGAC	CGCTGATCGT	CACGGCGATT	TATGCCGCCT	8200
CGGCGAGCAC	ATGGAACGGG	TTGGCATGGA	TTGTAGGCGC	CGCCCTATAC	8250
CTTGTCTGCC	TCCCCGCGTT	GCGTCGCGGT	GCATGGAGCC	GGGCCACCTC	8300
GACCTGAATG	GAAGCCGGCG	GCACCTCGCT	AACGGATTCA	CCACTCCAAG	8350
AATTGGAGCC	AATCAATTCT	TGCGGAGAAC	TGTGAATGCG	CAAACCAACC	8400
CTTGGCAGAA	CATATCCATC	GCGTCCGCCA	TCTCCAGCAG	CCGCACGCGG	8450
CGCATCTCGG	GCAGCGTTGG	GTCCTGGCCA	CGGGTGCGCA	TGATCGTGCT	8500
CCTGTCGTTG	AGGACCCGGC	TAGGCTGGCG	GGGTTCGCTT	ACTGGTTAGC	8550
AGAATGAATC	ACCGATACGC	GAGCGAACGT	GAAGCGACTG	CTGCTGCAAA	8600
ACGTCTGCGA	CCTGAGCAAC	AACATGAATG	GTCTTCGGTT	TCCGTGTTTC	8650
GTAAAGTCTG	GAAACGCGGA	AGTCAGCGCC	CTGCACCATT	ATGTTCCGGA	8700
TCTGCATCGC	AGGATGCTGC	TGGCTACCCT	GTGGAACACC	TACATCTGTA	8750
TTAACGAAGC	CTTTCTCAAT	GCTCACGCTG	TAGGTATCTC	AGTTCGGTGT	8800

AGGTCGTTTCG	CTCCAAGCTG	GGCTGTGTGC	ACGAACCCCC	CGTTCAGCCC	8850
GACCGCTGCG	CCTTATCCGG	TAACTATCGT	CTTGAGTCCA	ACCCGGTAAG	8900
ACACGACTTA	TCGCCACTGG	CAGCAGCCAC	TGGTAACAGG	ATTAGCAGAG	8950
CGAGGTATGT	AGGCGGTGCT	ACAGAGTTCT	TGAAGTGGTG	GCCTAACTAC	9000
GGCTACACTA	GAAGGACAGT	ATTTGGTATC	TGCGCTCTGC	TGAAGCCAGT	9050
TACCTTCGGA	AAAAGAGTTG	GTAGCTCTTG	ATCCGGCAAA	CAAACCACCG	9100
CTGGTAGCGG	TGGTTTTTTT	GTTTGCAAGC	AGCAGATTAC	GCGCAGAAAA	9150
AAAGGATCTC	AAGAAGATCC	TTTGATCTTT	TCTACGGGGT	CTGACGCTCA	9200
GTGGAACGAA	AACTCACGTT	AAGGGATTTT	GGTCATGAGA	TTATCAAAAA	9250
GGATCTTCAC	CTAGATCCTT	TTAAATTAAA	AATGAAGTTT	TAAATCAATC	9300
TAAAGTATAT	ATGAGTAAAC	TTGGTCTGAC	AGTTACCAAT	GCTTAATCAG	9350
TGAGGCACCT	ATCTCAGCGA	TCTGTCTATT	TCGTTTCATCC	ATAGTTGCCT	9400
GACTCCCCGT	CGTGTAGATA	ACTACGATAC	GGGAGGGCTT	ACCATCTGGC	9450
CCCAGTGCTG	CAATGATACC	GCGAGACCCA	CGCTCACCGG	CTCCAGATTT	9500
ATCAGCAATA	AACCAGCCAG	CCGGAAGGGC	CGAGCGCAGA	AGTGGTCCTG	9550
CAACTTTATC	CGCCTCCATC	CAGTCTATTA	ATTGTTGCCG	GGAAGCTAGA	9600
GTAAGTAGTT	CGCCAGTTAA	TAGTTTGCGC	AACGTTGTTG	CCATTGCTGC	9650
AGGCATCGTG	GTGTCACGCT	CGTCGTTTGG	TATGGCTTCA	TTCAGCTCCG	9700
GTTCCCAACG	ATCAAGGCGA	GTTACATGAT	CCCCCATGTT	GTGCAAAAAA	9750
GCGGTTAGCT	CCTTCGGTCC	TCCGATCGTT	GTCAGAAGTA	AGTTGGCCGC	9800
AGTGTTATCA	CTCATGGTTA	TGGCAGCACT	GCATAATTCT	CTTACTGTCA	9850
TGCCATCCGT	AAGATGCTTT	TCTGTGACTG	GTGAGTACTC	AACCAAGTCA	9900
TTCTGAGAAT	AGTGTATGCG	GCGACCGAGT	TGCTCTTGCC	CGGCGTCAAC	9950
ACGGGATAAT	ACCGCGCCAC	ATAGCAGAAC	TTTAAAAGTG	CTCATCATTG	10000
GAAAACGTTC	TTCGGGGCGA	AAACTCTCAA	GGATCTTACC	GCTGTTGAGA	10050
TCCAGTTCGA	TGTAACCCAC	TCGTGCACCC	AACTGATCTT	CAGCATCTTT	10100

57

TACTTTCACC	AGCGTTTCTG	GGTGAGCAAA	AACAGGAAGG	CAAAATGCCG	10150
CAAAAAAGGG	AATAAGGGCG	ACACGGAAAT	GTTGAATACT	CATACTCTTC	10200
CTTTTTCAAT	ATTATTGAAG	CATTTATCAG	GGTTATTGTC	TCATGAGCGG	10250
ATACATATTT	GAATGTATTT	AGAAAAATAA	ACAAATAGGG	GTTCCGCGCA	10300
CATTTCCCCG	AAAAGTGCCA	CCTGACGTCT	AAGAAACCAT	TATTATCATG	10350
ACATTAACCT	ATAAAAATAG	GCGTATCACG	AGGCCCTTTC	GTCTTCAA	10398

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4910 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TCGCGCGTTT	CGGTGATGAC	GGTGAAAACC	TCTGACACAT	GCAGCTCCCG	50
GAGACGGTCA	CAGCTTGTCT	GTAAGCGGAT	GCCGGGAGCA	GACAAGCCCG	100
TCAGGGCGCG	TCAGCGGGTG	TTGGCGGGTG	TCGGGGCTGG	CTTAACTATG	150
CGGCATCAGA	GCAGATTGTA	CTGAGAGTGC	ACCATATGCG	GTGTGAAATA	200
CCGCACAGAT	GCGTAAGGAG	AAAATACCGC	ATCAGGCGCC	ATTCGCCATT	250
CAGGCTGCGC	AACTGTTGGG	AAGGGCGATC	GGTGCGGGCC	TCTTCGCTAT	300
TACGCCAGCT	GGCGAAAGGG	GGATGTGCTG	CAAGGCGATT	AAGTTGGGTA	350
ACGCCAGGGT	TTTCCCAGTC	ACGACGTTGT	AAAACGACGG	CCAGTGCCAA	400
GCTTGCAATG	CTGCAGGTCT	ACTCTAGAGG	ATCCGAAAAA	ACCTCCACA	450
CCTCCCCCTG	AACCTGAAAC	ATAAAATGAA	TGCAATTGTT	GTTGTTAACT	500
TGTTTATTGC	AGCTTATAAT	GGTTACAAAT	AAAGCAATAG	CATCACAAAT	550
TTCACAAATA	AAGCATTTTT	TTCAGTGCAT	TCTAGTTGTG	GTTTGTCCAA	600
ACTCATCAAT	GTATCTTATC	ATGTCTGGAT	CCCCGCGGCC	GCCAAATCAT	650

TTATTGTTCA AAGATGCAGT CATCCAAATC CACATTGACC AGATCGCAGG	700
CAGTGCAAGC GTCTGGCACC TTTCCCATGA TATGATGAAT GTAGCACAGT	750
TTCTGATACG CCTTTTGTGAC GACAGAAACG GGTGAGATT CTGACACGGG	800
AAAGCACTCT AAACAGTCTT TCTGTCCGTG AGTGAGCAG ATATTTGAAT	850
TCTGATTCAT TCTCTCGCAT TGTCTGCAGG GAAACAGCAT CAGATTCATG	900
CCCACGTGAC GAGAACATTT GTTTTGGTAC CTGTCTGCGT AGTTGATCGA	950
AGCTTCCGCG TCTGACGTCG ATGGCTGCGC AACTGACTCG CGCACCCGTT	1000
TGGGCTCACT TATATCTGCG TCACTGGGGG CGGGTCTTTT CTTGGCTCCA	1050
CCCTTTTGA CGTAGAATTC ATGCTCCACC TCAACCACGT GATCCTTTGC	1100
CCACCGGAAA AAGTCTTTGA CTTCTGCTT GGTGACCTT CCAAAGTCAT	1150
GATCCAGACG GCGGGTGAGT TCAAATTTGA ACATCCGGTC TTGCAACGGC	1200
TGCTGGTGTT CGAAGGTCGT TGAGTTCCCG TCAATCACGG CGCACATGTT	1250
GGTGTTGGAG GTGACGATCA CGGGAGTCGG GTCTATCTGG GCCGAGGACT	1300
TGCATTTCTG GTCCACGCGC ACCTTGCTTC CTCCGAGAAT GGCTTTGGCC	1350
GACTCCACGA CCTTGGCGGT CATCTTCCCC TCCTCCCACC AGATCACCAT	1400
CTTGTCGACA CAGTCGTTGA AGGGAAAGTT CTCATTGGTC CAGTTTACGC	1450
ACCCGTAGAA GGGGAGAGTG TGGGCTATGG CCTCCGCGAT GTTGGTCTTC	1500
CCGGTAGTTG CAGGCQCAA CAGCCAGATG GTGTTCTCT TGCCGAACCT	1550
TTTCGTGGCC CATCCAGAA AGACGGAAGC CGCATATTGG GGATCGTACC	1600
CGTTTAGTTC CAAAATTTTA TAAATCCGAT TGCTGGAAT GTCTCCACG	1650
GGCTGCTGGC CCACCAGGTA GTCGGGGGCG GTTTTAGTCA GGCTCATAAT	1700
CTTTCCCGCA TTGTCCAAGG CAGCCTTGAT TTGGGACCGC GAGTTGGAGG	1750
CCGCATTGAA GGAGATGTAT GAGGCCTGGT CCTCCTGGAT CCACTGCTTC	1800
TCCGAGGTAA TCCCCTTGTC CACGAGCCAC CCGACCAGCT CCATGTACCT	1850
GGCTGAAGTT TTTGATCTGA TCACCGGCGC ATCAGAATTG GGATTCTGAT	1900
TCTCTTTGTT CTGCTCCTGC GTCTGCGACA CGTGCGTCAG ATGCTGCGCC	1950

ACCAACCGTT	TACGCTCCGT	GAGATTCAAA	CAGGCGCTTA	AATACTGTTC	2000
CATATTAGTC	CACGCCCCT	GGAGCTCAGG	CTGGGTTTTG	GGGAGCAAGT	2050
AATTGGGGAT	GTAGCACTCA	TCCACCACCT	TGTTCCCGCC	TCCGGCGCCA	2100
TTTCTGGTCT	TTGTGACCGC	GAACCAGTTT	GGCAAAGTCG	GCTCGATCCC	2150
GCGGTAAATT	CTCTGAATCA	GTTTTTCGCG	AATCTGACTC	AGGAAACGTC	2200
CCAAAACCAT	GGATTTACAC	CCGGTGGTTT	CCACGAGCAC	GTGCATGTGG	2250
AAGTAGCTCT	CTCCCTTCTC	AAATTGCACA	AAGAAAAGGG	CCTCCGGGGC	2300
CTTACTCACA	CGGCGCCATT	CCGTCAGAAA	GTCGCGCTGC	AGCTTCTCGG	2350
CCACGGTCAG	GGGTGCCTGC	TCAATCAGAT	TCAGATCCAT	GTCAGAATCT	2400
GGCGGCAACT	CCCATTCCCT	CTCGGCCACC	CAGTTCACAA	AGCTGTCAGA	2450
AATGCCGGGC	AGATGCCCCG	CAAGGTCGCT	GGGGACCTTA	ATCACAATCT	2500
CGTAAAACCC	CGGCATGGCG	GCTGCGCGTT	CAAACCTCCC	GCTTCAAAAT	2550
GGAGACCCTG	CGTGCTCACT	CGGGCTTAAA	TACCCAGCGT	GACCACATGG	2600
TGTCGCAAAA	TGTCGCAAAA	CACTCACGTG	ACCTCTAATA	CAGGACTCTA	2650
GAGGATCCCC	GGGTACCGAG	CTCGAATTCG	TAATCATGGT	CATAGCTGTT	2700
TCCTGTGTGA	AATTGTTATC	CGCTCACAAT	TCCACACAAC	ATACGAGCCG	2750
GAAGCATAAA	GTGTAAAGCC	TGGGGTGCCT	AATGAGTGAG	CTAACTCACA	2800
TTAATTGCGT	TGCGCTCACT	GCCCGCTTTC	CAGTCGGGAA	ACCTGTCGTG	2850
CCAGCTGCAT	TAATGAATCG	GCCAACGCGC	GGGGAGAGGC	GGTTTGCGTA	2900
TTGGGCGCTC	TTCCGCTTCC	TCGCTCACTG	ACTCGCTGCG	CTCGGTCGTT	2950
CGGCTGCGGC	GAGCGGTATC	AGCTCACTCA	AAGGCGGTAA	TACGGTTATC	3000
CACAGAATCA	GGGGATAACG	CAGGAAAGAA	CATGTGAGCA	AAAGGCCAGC	3050
AAAAGGCCAG	GAACCGTAAA	AAGGCCGCGT	TGCTGGCGTT	TTTCCATAGG	3100
CTCCGCCCCC	CTGACGAGCA	TCACAAAAAT	CGACGCTCAA	GTCAGAGGTG	3150
GCGAAACCCG	ACAGGACTAT	AAAGATACCA	GGCGTTTCCC	CCTGGAAGCT	3200
CCCTCGTGCG	CTCTCCTGTT	CCGACCCTGC	CGCTTACCGG	ATACCTGTCC	3250

60

GCCTTCTCC	CTTCGGAAG	CGTGGCGCTT	TCTCATAGCT	CACGCTGTAG	3300
GTATCTCAGT	TCGGTGTAGG	TCGTTCGCTC	CAAGCTGGGC	TGTGTGCACG	3350
AACCCCCCGT	TCAGCCCGAC	CGCTGCGCCT	TATCCGGTAA	CTATCGTCTT	3400
GAGTCCAACC	CGGTAAGACA	CGACTTATCG	CCACTGGCAG	CAGCCACTGG	3450
TAACAGGATT	AGCAGAGCGA	GGTATGTAGG	CGGTGCTACA	GAGTTCTTGA	3500
AGTGGTGGCC	TAACCTACGGC	TACACTAGAA	GGACAGTATT	TGGTATCTGC	3550
GCTCTGCTGA	AGCCAGTTAC	CTTCGGAAAA	AGAGTTGGTA	GCTCTTGATC	3600
CGGCAAACAA	ACCACCGCTG	GTAGCGGTGG	TTTTTTTGT	TGCAAGCAGC	3650
AGATTACGCG	CAGAAAAAAA	GGATCTCAAG	AAGATCCTTT	GATCTTTTCT	3700
ACGGGGTCTG	ACGCTCAGTG	GAACGAAAAC	TCACGTTAAG	GGATTTTGGT	3750
CATGAGATTA	TCAAAAAGGA	TCTTCACCTA	GATCCTTTTA	AATTAAAAAT	3800
GAAGTTTAA	ATCAATCTAA	AGTATATATG	AGTAAACTTG	GTCTGACAGT	3850
TACCAATGCT	TAATCAGTGA	GGCACCTATC	TCAGCGATCT	GTCTATTTCTG	3900
TTCATCCATA	GTTGCCTGAC	TCCCCGTCGT	GATGATAACT	ACGATACGGG	3950
AGGGCTTACC	ATCTGGCCCC	AGTGCTGCAA	TGATACCGCG	AGACCCACGC	4000
TCACCGGCTC	CAGATTTATC	AGCAATAAAC	CAGCCAGCCG	GAAGGGCCGA	4050
GCGCAGAAGT	GGTCCTGCAA	CTTTATCCGC	CTCCATCCAG	TCTATTAATT	4100
GTTGCCGGGA	AGCTAGAGTA	AGTAGTTCGC	CAGTTAATAG	TTTGCGCAAC	4150
GTTGTTGCCA	TTGCTACAGG	CATCGTGGTG	TCACGCTCGT	CGTTTGGTAT	4200
GGCTTCATTC	AGCTCCGGTT	CCCAACGATC	AAGGCGAGTT	ACATGATCCC	4250
CCATGTTGTG	CAAAAAGCG	GTTAGCTCCT	TCGGTCCTCC	GATCGTTGTC	4300
AGAAGTAAGT	TGGCCGAGT	GTTATCACTC	ATGGTTATGG	CAGCACTGCA	4350
TAATTCTCTT	ACTGTCATGC	CATCCGTAAG	ATGCTTTTCT	GTGACTGGTG	4400
AGTACTCAAC	CAAGTCATTC	TGAGAATAGT	GTATGCGGCG	ACCGAGTTGC	4450
TCTTGCCCGG	CGTCAATACG	GGATAATACC	GCGCCACATA	GCAGAACTTT	4500
AAAAGTGCTC	ATCATTTGAA	AACGTTCTTC	GGGGCGAAAA	CTCTCAAGGA	4550

61

TCTTACCGCT	GTTGAGATCC	AGTTCGATGT	AACCCACTCG	TGCACCCAAC	4600
TGATCTTCAG	CATCTTTTAC	TTTCACCAGC	GTTTCTGGGT	GAGCAAAAAC	4650
AGGAAGGCAA	AATGCCGCAA	AAAAGGGAAT	AAGGGCGACA	CGGAAATGTT	4700
GAATACTCAT	ACTCTTCCTT	TTTCAATATT	ATTGAAGCAT	TTATCAGGGT	4750
TATTGTCTCA	TGAGCGGATA	CATATTTGAA	TGTATTTAGA	AAAATAAACA	4800
AATAGGGGTT	CCGCGCACAT	TTCCCCGAAA	AGTGCCACCT	GACGTCTAAG	4850
AAACCATTAT	TATCATGACA	TTAACCTATA	AAAATAGGCG	TATCAGGAGG	4900
CCCTTTCGTC					4910

## WHAT IS CLAIMED IS.

1. A recombinant hybrid virus comprising:
  - (a) DNA sequences of, or corresponding to, the 5' inverted terminal repeat (ITR) sequences of an adenovirus and the 5' adenovirus packaging/enhancer domain;
  - (b) DNA sequences of, or corresponding to, the 5' adeno-associated virus (AAV) ITR sequences;
  - (c) a gene encoding a selected protein operatively linked to regulatory sequences directing expression of the protein in a target cell in vivo or in vitro;
  - (d) DNA sequences of, or corresponding to, the 3' AAV ITR sequences;
  - (e) DNA sequences of, or corresponding to, the 3' adenovirus ITR sequences;wherein said virus is replication-defective and is provided with a sufficient portion of the genome of the adenovirus to permit infection of the target cell.
2. The virus according to claim 1 wherein said adenovirus is rendered replication defective by a deletion in all or a part of the E1 gene.
3. The virus according to claim 2 wherein said adenovirus genome has a deletion in all or a part of the E3 gene.

4. The virus according to claim 1 wherein said adenovirus genome comprising deletions in the DNA sequences of all or a portion of the adenovirus genes selected from the group consisting of the E2a gene, the E4 gene, the late genes L1 through L5, the intermediate genes IX and IV<sub>a</sub>, and a combination thereof.

5. The virus according to claim 1 wherein said selected gene is a reporter gene.

6. The virus according to claim 5 wherein said reporter gene is selected from the group consisting of the genes encoding  $\beta$ -galactosidase, alkaline phosphatase and green fluorescent protein.

7. The virus according to claim 1 wherein said selected gene is a therapeutic gene.

8. The virus according to claim 7 wherein said therapeutic gene is selected from the group consisting of a normal CFTR gene and a normal LDL gene.

9. The virus according to claim 1 further comprising the DNA of, or corresponding to, a functional portion of the genome of an adeno-associated virus rep gene.

10. A recombinant hybrid vector comprising:  
(a) DNA sequences of, or corresponding to, the 5' inverted terminal repeat (ITR) sequences of an adenovirus and the 5' adenovirus packaging/enhancer domain;

(b) DNA sequences of, or corresponding to, the 5' adeno-associated virus (AAV) ITR sequences;

(c) a gene encoding a selected protein operatively linked to regulatory sequences directing expression of the protein in a target cell in vivo or in vitro;

(d) DNA sequences of, or corresponding to, the 3' AAV ITR sequences;

(e) DNA sequences of, or corresponding to, the 3' adenovirus ITR sequences; and

(d) plasmid DNA sequences containing regulatory elements.

~~11.12~~ A recombinant trans-infection particle comprising:

(a) a recombinant hybrid virus comprising:

(i) DNA sequences of, or corresponding to, the 5' inverted terminal repeat (ITR) sequences of an adenovirus and the 5' adenovirus packaging/enhancer domain;

(ii) DNA sequences of, or corresponding to, the 5' adeno-associated virus (AAV) ITR sequences;

(iii) a gene encoding a selected protein operatively linked to regulatory sequences directing expression of the protein in a target cell in vivo or in vitro;

(iv) DNA sequences of, or corresponding to, the 3' AAV ITR sequences;

(v) DNA sequences of, or corresponding to, the 3' adenovirus ITR sequences;

wherein said virus is replication-defective and is provided with a sufficient portion of the genome of the adenovirus to permit infection of the target cell;

(b) a polycation sequence conjugated to said hybrid virus; and

(c) a plasmid comprising an AAV rep gene operatively linked to regulatory sequences capable of directing its expression, said plasmid associated with said polycation sequence.

12. The trans-infection particle according to claim 11 wherein said adenovirus DNA lacks the sequence encoding viral genes.

13. The trans-infection particle according to claim 11 wherein said adenovirus genome is rendered replication-defective by a deletion in all or a part of the E1 gene.

14. The particle according to claim 13 wherein said adenovirus genome has a deletion in all or a part of the E3 gene.

15. The particle according to claim 11 wherein said adenovirus genome has deletions in the DNA sequences of all or a portion of the adenovirus genes selected from the group consisting of the E2a gene, the E4 gene, the late genes L1 through L5, the intermediate genes IX and IV<sub>a</sub>, and a combination thereof.

16. The particle according to claim 11 wherein said selected gene is a reporter gene.

17. The particle according to claim 16 wherein said reporter gene is selected from the group consisting of the genes encoding  $\beta$ -galactosidase, alkaline phosphatase and green fluorescent protein.

18. The particle according to claim 11 wherein said selected gene is a therapeutic gene.

19. The particle according to claim 18 wherein said therapeutic gene is selected from the group consisting of a normal CFTR gene and a normal LDL gene.

20. A composition for use in delivering and stably integrating a selected gene into the chromosome of a target cell, said composition comprising

(a) a recombinant hybrid virus comprising:

(i) DNA sequences of, or corresponding to, the 5' inverted terminal repeat (ITR) sequences of an adenovirus and the 5' adenovirus packaging/enhancer domain;

(ii) DNA sequences of, or corresponding to, the 5' adeno-associated virus (AAV) ITR sequences;

(iii) a gene encoding a selected protein operatively linked to regulatory sequences directing expression of the protein in a target cell in vivo or in vitro;

(iv) DNA sequences of, or corresponding to, the 3' AAV ITR sequences;

(v) DNA sequences of, or corresponding to, the 3' adenovirus ITR sequences;

wherein said virus is replication-defective and is provided with a sufficient portion of the genome of the adenovirus to permit infection of the target cell; and

(b) a pharmaceutically acceptable carrier.

21. The composition according to claim 20 further comprising a plasmid comprising an AAV rep gene under the control of regulatory sequences capable of expressing said rep gene in said target cell.

22. The composition according to claim 21 wherein said vector further comprises the DNA of, or corresponding to, at least a functional portion of the genome of an adeno-associated virus rep gene.

23. A composition for use in delivering and stably integrating a selected gene into the chromosome of a target cell comprising an effective amount of a recombinant trans-infection particle in a pharmaceutically acceptable carrier, said particle comprising:

(a) a recombinant hybrid virus comprising:  
(i) DNA sequences of, or corresponding to, the 5' inverted terminal repeat (ITR) sequences of an adenovirus and the 5' adenovirus packaging/enhancer domain;

(ii) DNA sequences of, or corresponding to, the 5' adeno-associated virus (AAV) ITR sequences;

(iii) a gene encoding a selected protein operatively linked to regulatory sequences directing expression of the protein in a target cell in vivo or in vitro;

(iv) DNA sequences of, or corresponding to, the 3' AAV ITR sequences;

(v) DNA sequences of, or corresponding to, the 3' adenovirus ITR sequences;

wherein said virus is replication-defective and is provided with a sufficient portion of the genome of the adenovirus to permit infection of the target cell;

(b) a polycation sequence conjugated to said hybrid virus;

(c) a plasmid comprising an AAV rep gene operatively linked to regulatory sequences capable of directing its expression, said plasmid associated with said polycation sequence.

24. A mammalian cell capable of expressing a selected gene introduced therein through transduction of the virus of claim 1, the vector of claim 10, or the trans-infection particle of claim 11.

25. A method for producing high levels of a recombinant adeno-associated virus comprising the steps of

(a) culturing a cell co-transfected with the vector of claim 10 and an optional helper virus in the presence of a plasmid containing an AAV rep gene under the control of regulatory sequences capable of expressing said rep gene; and

(b) isolating from said culture a recombinant AAV.

26. A method for producing high levels of a recombinant adeno-associated virus comprising the steps of

(a) culturing a cell transfected with the particle of claim 11 and

(b) isolating from said culture a recombinant AAV.

1/21




FIG. 1A




FIG. 1B

CO-TRANSFECTION INTO  
293 CELLS FOLLOWED BY  
INTRACELLULAR HOMOLOGOUS  
RECOMBINATION.




FIG. 1C

2/21

## FIGURE 2A

GAATTCGCTA GCATCATCAA TAATATACCT TATTTTGGAT TGAAGCCAAT ATGATAATGA  
60

GGGGGTGGAG TTTGTGACGT GGC GCGGGG GTGGGAACGG GCGGGGTGAC GTAGTAGTGT  
120

GGCGGAAGTG TGATGTTGCA AGTGTGGCGG AACACATGTA AGCGACGGAT GTGGCAAAAG  
180

TGACGTTTTT GGTGTGCGCC GGTGTACACA GGAAGTGACA ATTTTCGCGC GGTTTTAGGC  
240

GGATGTTGTA GTAAATTTGG GCGTAACCGA GTAAGATTG GCCATTTTCG CGGGAAACT  
300

GAATAAGAGG AAGTGAAATC TGAATAATTT TGTGTTACTC ATAGCGCGTA ATATTTGTCT  
360

AGGGAGATCT GCTGCGCGCT CGCTCGCTCA CTGAGGCCGC CCGGGCAAAG CCCGGGCGTC  
420

GGGCGACCTT TGGTCGCCCC GCCTCAGTGA GCGAGCGAGC GCGCAGAGAG GGAGTGGCCA  
480

ACTCCATCAC TAGGGGTTCC TTGTAGTTAA TGATTAACCC GCCATGCTAC TTATCTACAA  
540

TTGAGCTTG CATGCCTGCA GGTCGTTACA TAACTTACGG TAAATGGCCC GCCTGGCTGA  
600

CCGCCCCAAG ACCCCCGCCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA  
660

ATAGGGACTT TCCATTGACG TCAATGGGTG GAGTATTTAC GGTAAACTGC CCACTTGGCA  
720

GTACATCAAG TGTATCATAT GCCAAGTACG CCCCTATTG ACGTCAATGA CGGTAAATGG  
780

CCCGCCTGGC ATTATGCCCA GTACATGACC TTATGGGACT TTCCTACTTG GCAGTACATC  
840

TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT CAATGGGCGT  
900

GGATAGCGGT TTGACTCAGG GGGATTTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT  
960

TTGTTTTGGC ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC CGCCCCATTG  
1020

3/21

## FIGURE 2B

ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGAGC TCGTTTAGTG  
1080

AACCGTCAGA TCGCCTGGAG ACGCCATCCA CGCTGTTTTG ACCTCCATAG AAGACACCGG  
1140

GACCGATCCA GCCTCCGGAC TCTAGAGGAT CCGGTACTCG AGGAACTGAA AAACCAGAAA  
1200

GTAACTGGT AAGTTTAGTC TTTTGTCTT TTATTCAGG TCCCGGATCC GGTGGTGGTG  
1260

CAAATCAAAG AACTGCTCCT CAGTGGATGT TGCCTTTACT TCTAGGCCTG TACGGAAGTG  
1320

TTACTTCTGC TCTAAAAGCT GCGGAATTGT ACCCGCGGCC GCAATTCCCG GGGATCGAAA  
1380

GAGCCTGCTA AAGCAAAAAA GAAGTCACCA TGTCGTTTAC TTTGACCAAC AAGAACGTGA  
1440

TTTTCGTTGC CGGTCTGGGA GGCATTGGTC TGGACACCAG CAAGGAGCTG CTCAAGCGCG  
1500

ATCCCGTCGT TTTACAACGT CGTGACTGGG AAAACCCTGG CGTTACCCAA CTTAATCGCC  
1560

TTGCAGCACA TCCCCCTTTC GCCAGCTGGC GTAATAGCGA AGAGGCCCGC ACCGATCGCC  
1620

CTTCCCAACA GTTGCGCAGC CTGAATGGCG AATGGCGCTT TGCCTGGTTT CCGGCACCAG  
1680

AAGCGGTGCC GGAAAGCTGG CTGGAGTGCG ATCTTCCTGA GGCCGATACT GTCGTCGTCC  
1740

CCTCAAACCTG GCAGATGCAC GGTTACGATG CGCCCATCTA CACCAACGTA ACCTATCCCA  
1800

TTACGGTCAA TCCGCCGTTT GTTCCCACGG AGAATCCGAC GGGTTGTTAC TCGCTCACAT  
1860

TTAATGTTGA TGAAAGCTGG CTACAGGAAG GCCAGACGCG AATTATTTTT GATGGCGTTA  
1920

ACTCGGCGTT TCATCTGTGG TGCAACGGGC GCTGGGTCGG TTACGGCCAG GACAGTCGTT  
1980

TGCCGTCTGA ATTTGACCTG AGCGCATTTT TACGCGCCGG AGAAAACCGC CTCGCGGTGA  
2040

4/21

## FIGURE 2C

TGGTGCTGCG TTGGAGTGAC GGCAGTTATC TGGAGATCA GGATATGTGG CGGATGAGCG  
2100

GCATTTTCCG TGACGTCTCG TTGCTGCATA AACCGACTAC ACAAATCAGC GATTTCCATG  
2160

TTGCCACTCG CTTTAATGAT GATTTCAGCC GCGCTGTACT GGAGGCTGAA GTTCAGATGT  
2220

GCGGCGAGTT GCGTGACTAC CTACGGGTAA CAGTTTCTTT ATGGCAGGGT GAAACGCAGG  
2280

TCGCCAGCGG CACCGCGCCT TTCGGCGGTG AAATTATCGA TGAGCGTGGT GGTTATGCCG  
2340

ATCGCGTCAC ACTACGTCTG AACGTCGAAA ACCCGAACT GTGGAGCGCC GAAATCCCGA  
2400

ATCTCTATCG TGCGGTGGTT GAACTGCACA CCGCCGACGG CACGCTGATT GAAGCAGAAG  
2460

CCTGCGATGT CGGTTTCCGC GAGGTGCGGA TTGAAAATGG TCTGCTGCTG CTGAACGGCA  
2520

AGCCGTTGCT GATTCGAGGC GTTAACCGTC ACGAGCATCA TCCTCTGCAT GGTCAGGTCA  
2580

TGGATGAGCA GACGATGGTG CAGGATATCC TGCTGATGAA GCAGAACAAC TTTAACGCCG  
2640

TGCGCTGTTT GCATTATCCG AACCATCCGC TGTGGTACAC GCTGTGCGAC CGCTACGGCC  
2700

TGTATGTGGT GGATGAAGCC AATATTGAAA CCCACGGCAT GGTGCCAATG AATCGTCTGA  
2760

CCGATGATCC GCGCTGGCTA CCGGCGATGA GCGAACGCGT AACGCGAATG GTGCAGCGCG  
2820

ATCGTAATCA CCCGAGTGTG ATCATCTGGT CGCTGGGGAA TGAATCAGGC CACGGCGCTA  
2880

ATCAGGACGC GCTGTATCGC TGGATCAAAT CTGTGATCC TTCCCGCCCC GTGCAGTATG  
2940

AAGGCGGCGG AGCCGACACC ACGGCCACCG ATATTATTTG CCCGATGTAC GCGCGCGTGG  
3000

ATGAAGACCA GCCCTTCCCG GCTGTGCCGA AATGGTCCAT CAAAAAATGG CTTTCGCTAC  
3060

5/21

## FIGURE 2D

CTGGAGAGAC GCGCCCGCTG ATCCTTTGCG AATACGCCCA CGCGATGGGT AACAGTCTTG  
3120

GCGGTTTCGC TAAATACTGG CAGGCGTTTC GTCAGTATCC CCGTTTACAG GGCGGCTTCG  
3180

TCTGGGACTG GGTGGATCAG TCGCTGATTA AATATGATGA AAACGGCAAC CCGTGGTCGG  
3240

CTTACGGCGG TGATTTTGGC GATACGCCGA ACGATCGCCA GTTCTGTATG AACGGTCTGG  
3300

TCTTTGCCGA CCGCACGCCG CATCCAGCGC TGACGGAAGC AAAACACCAG CAGCAGTTTT  
3360

TCCAGTTCCG TTTATCCGGG CAAACCATCG AAGTGACCAG CGAATACCTG TTCCGTCATA  
3420

GCGATAACGA GCTCCTGCAC TGGATGGTGG CGCTGGATGG TAAGCCGCTG GCAAGCGGTG  
3480

AAGTGCCTCT GGATGTCGCT CCACAAGGTA AACAGTTGAT TGAAGTGCCT GAACTACCGC  
3540

AGCCGGAGAG CGCCGGGCAA CTCTGGCTCA CAGTACGCGT AGTGCAACCG AACCGGACCG  
3600

CATGGTCAGA AGCCGGGCAC ATCAGCGCCT GGCAGCAGTG GCGTCTGGCG GAAAACCTCA  
3660

GTGTGACGCT CCCC GCCGCG TCCCACGCCA TCCCGCATCT GACCACCAGC GAAATGGATT  
3720

TTTGCATCGA GCTGGGTAAT AAGCGTTGGC AATTTAACCG CCAGTCAGGC TTTCTTTTAC  
3780

AGATGTGGAT TGGCGATAAA AAACAACTGC TGACGCCGCT GCGCGATCAG TTCACCCGTG  
3840

CACCGCTGGA TAACGACATT GCGGTAAGTG AAGCGACCCG CATTGACCCT AACGCCTGGG  
3900

TCGAACGCTG GAAGGCGGCG GGCCATTACC AGGCCGAAGC AGCGTTGTTG CAGTGCACGG  
3960

CAGATACACT TGCTGATGCG GTGCTGATTA CGACCGCTCA CGCGTGGCAG CATCAGGGGA  
4020

AAACCTTATT TATCAGCCGG AAAACCTACC GGATTGATGG TAGTGGTCAA ATGGCGATTA  
4080

6/21

## FIGURE 2E

CCGTTGATGT TGAAGTGGCG AGCGATACAC CGCATCCGGC GCGGATTGGC CTGAACTGCC  
4140

AGCTGGCGCA GGTAGCAGAG CGGGTAAACT GGCTCGGATT AGGGCCGCAA GAAAACTATC  
4200

CCGACCGCCT TACTGCCGCC TGTTTTGACC GCTGGGATCT GCCATTGTCA GACATGTATA  
4260

CCCCGTACGT CTTCCCGAGC GAAAACGGTC TCGCTGCGG GACGCGCGAA TTGAATTATG  
4320

GCCACACCA GTGGCGCGGC GACTTCCAGT TCAACATCAG CCGCTACAGT CAACAGCAAC  
4380

TGATGGAAAC CAGCCATCGC CATCTGCTGC ACGCGGAAGA AGGCACATGG CTGAATATCG  
4440

ACGGTTTCCA TATGGGGATT GGTGGCGACG ACTCCTGGAG CCCGTCAGTA TCGGCGGAAT  
4500

TACAGCTGAG CGCCGGTGGC TACCATTACC AGTTGGTCTG GTGTCAAAAA TAATAATAAC  
4560

CGGGCAGGCC ATGTCTGCCC GTATTTGCGG TAAGGAAATC CATTATGTAC TATTTAAAAA  
4620

ACACAAACTT TTGGATGTTT GGTATTATTCT TTTTCTTTTA CTTTTTTATC ATGGGAGCCT  
4680

ACTTCCCGTT TTTCCCGATT TGGCTACATG ACATCAACCA TATCAGCAAA AGTGATACGG  
4740

GTATTATTTT TGCCGCTATT TCTCTGTTCT CGCTATTATT CCAACCGCTG TTTGGTCTGC  
4800

TTTCTGACAA ACTCGGCCTC GACTCTAGGC GGCCGCGGGG ATCCAGACAT GATAAGATAC  
4860

ATTGATGAGT TTGGACAAAC CACAACTAGA ATGCAGTGAA AAAAATGCTT TATTTGTGAA  
4920

ATTTGTGATG CTATTGCTTT ATTTGTAACC ATTATAAGCT GCAATAAACA AGTTAACAAC  
4980

AACAATTGCA TTCATTTTAT GTTTCAGGTT CAGGGGGAGG TGTGGGAGGT TTTTTCGGAT  
5040

CCTCTAGAGT CGAGTAGATA AGTAGCATGG CGGGTTAATC ATTAACCTACA AGGAACCCCT  
5100

7/21

## FIGURE 2F

AGTGATGGAG TTGGCCACTC CCTCTCTGCG CGCTCGCTCG CTCACTGAGG CCGGGCGACC  
5160

AAAGGTCGCC CGACGCCCCG GCTTTGCCCC GCGGGCCTCA GTGAGCGAGC GAGCGCGCAG  
5220

CAGATCTGGA AGGTGCTGAG GTACGATGAG ACCCGCACCA GGTGCAGACC CTGCGAGTGT  
5280

GGCGGTAAAC ATATTAGGAA CCAGCCTGTG ATGCTGGATG TGACCGAGGA GCTGAGGCCC  
5340

GATCACTTGG TGCTGGCCTG CACCCGCGCT GAGTTTGGCT CTAGCGATGA AGATACAGAT  
5400

TGAGGTACTG AAATGTGTGG GCGTGGCTTA AGGGTGGGAA AGAATATATA AGGTGGGGGT  
5460

CTTATGTAGT TTTGTATCTG TTTTGCAGCA GCCGCCGCCG CCATGAGCAC CAACTCGTTT  
5520

GATGGAAGCA TTGTGAGCTC ATATTTGACA ACGCGCATGC CCCCATGGGC CGGGGTGCGT  
5580

CAGAATGTGA TGGGCTCCAG CATTGATGGT CGCCCCGTCC TGCCCGCAAA CTCTACTACC  
5640

TTGACCTACG AGACCGTGTC TGGAACGCCG TTGGAGACTG CAGCCTCCGC CGCCGCTTCA  
5700

GCCGCTGCAG CCACCGCCCC CGGGATTGTG ACTGACTTTG CTTTCCTGAG CCCGCTTGCA  
5760

AGCAGTGCAG CTTCCCGTTC ATCCGCCCGC GATGACAAGT TGACGGCTCT TTTGGCACAA  
5820

TTGGATTCTT TGACCCGGGA ACTTAATGTC GTTTCTCAGC AGCTGTTGGA TCTGCGCCAG  
5880

CAGGTTTCTG CCCTGAAGGC TTCCTCCCCT CCCAATGCGG TTAAACAT AAATAAAAAA  
5940

CCAGACTCTG TTTGGATTTG GATCAAGCAA GTGTCTTGCT GTCTTTATTT AGGGGTTTTG  
6000

CGCGCGCGGT AGGCCCCGGA CCAGCGGTCT CGGTCGTTGA GGGTCCTGTG TATTTTTTCC  
6060

AGGACGTGGT AAAGGTGACT CTGGATGTTT AGATACATGG GCATAAGCCC GTCTCTGGGG  
6120

8/21

## FIGURE 2G

TGGAGGTAGC ACCACTGCAG AGCTTCATGC TCGGGGGTGG TGTTGTAGAT GATCCAGTCG  
6180

TAGCAGGAGC GCTGGGCGTG GTGCCTAAAA ATGTCTTTCA GTAGCAAGCT GATTGCCAGG  
6240

GGCAGGCCCT TGGTGTAAGT GTTTACAAAG CGGTTAAGCT GGGATGGGTG CATACGTGGG  
6300

GATATGAGAT GCATCTTGGA CTGTATTTTT AGGTTGGCTA TGTTCCCAGC CATATCCCTC  
6360

CGGGGATTCA TGTTGTGCAG AACCACCAGC ACAGTGTATC CGGTGCACTT GGGAAATTTG  
6420

TCATGTAGCT TAGAAGGAAA TCGTGGAAG AACTTGGAGA CGCCCTTGTG ACCTCCAAGA  
6480

TTTTCCATGC ATTCGTCCAT AATGATGGCA ATGGGCCAC GGGCGGCGGC CTGGGCGAAG  
6540

ATATTTCTGG GATCACTAAC GTCATAGTTG TGTTCCAGGA TGAGATCGTC ATAGGCCATT  
6600

TTTACAAAGC GCGGGCGGAG GGTGCCAGAC TCGGGTATAA TGTTTCCATC CGGCCAGGG  
6660

GCGTAGTTAC CCTCACAGAT TTGCATTTCC CACGCTTTGA GTTCAGATGG GGGGATCATG  
6720

TCTACCTGCG GGGCGATGAA GAAAACGGTT TCCGGGGTAG GGGAGATCAG CTGGGAAGAA  
6780

AGCAGGTTC TGAGCAGCTG CGACTTACCG CAGCCGGTGG GCCCGTAAAT CACACCTATT  
6840

ACCGGGTGCA ACTGGTAGTT AAGAGAGCTG CAGCTGCCGT CATCCCTGAG CAGGGGGGGC  
6900

ACTTCGTTAA GCATGTCCCT GACTCGCATG TTTTCCCTGA CCAAATCCGC CAGAAGGCGC  
6960

TCGCCGCCCA GCGATAGCAG TTCTTGCAAG GAAGCAAAGT TTTTCAACGG TTTGAGACCG  
7020

TCCGCCGTAG GCATGCTTTT GAGCGTTTGA CCAAGCAGTT CCAGGCGGTC CCACAGCTCG  
7080

GTCACCTGCT CTACGGCATC TCGATCCAGC ATATCTCCTC GTTTCGCGGG TTGGGGCGGG  
7140

9/21

## FIGURE 2H

TTTCGCTGTA CGGCAGTAGT CGGTGCTCGT CCAGACGGGC CAGGGTCATG TCTTTCCACG  
7200

GGCGCAGGGT CCTCGTCAGC GTAGTCTGGG TCACGGTGAA GGGGTGCGCT CCGGGCTGCG  
7260

CGCTGGCCAG GGTGCGCTTG AGGCTGGTCC TGCTGGTGCT GAAGCGCTGC CGGTCTTCGC  
7320

CCTGCGCGTC GGCCAGGTAG CATTGACCA TGGTGCATA GTCCAGCCCC TCCGCGGCGT  
7380

GGCCCTTGGC GCGCAGCTTG CCCTTGAGG AGGCGCCGCA CGAGGGGCAG TGCAGACTTT  
7440

TGAGGGCGTA GAGCTTGGGC GCGAGAAATA CCGATTCCGG GGAGTAGGCA TCCGCGCCGC  
7500

AGGCCCCGCA GACGGTCTCG CATTCCACGA GCCAGGTGAG CTCTGGCCGT TCGGGGTCAA  
7560

AAACCAGGTT TCCCCATGC TTTTGTATGC GTTTCTTACC TCTGGTTTCC ATGAGCCGGT  
7620

GTCCACGCTC GGTGACGAAA AGGCTGTCCG TGTCCCCGTA TACAGACTTG AGAGGCCTGT  
7680

CCTCGACCGA TGCCCTTGAG AGCCTTCAAC CCAGTCAGCT CCTTCCGGTG GCGCGGGGC  
7740

ATGACTATCG TCGCCGCACT TATGACTGTC TTCTTTATCA TGCAACTCGT AGGACAGGTG  
7800

CCGGCAGCGC TCTGGGTCAT TTTCGGCGAG GACCGCTTTC GCTGGAGCGC GACGATGATC  
7860

GGCCTGTGCG TTGCGGTATT CGGAATCTTG CACGCCCTCG CTCAAGCCTT CGTCACTGGT  
7920

CCCGCCACCA AACGTTTCGG CGAGAAGCAG GCCATTATCG CCGGCATGGC GGCCGACGCG  
7980

CTGGGCTACG TCTTGCTGGC GTTCGCGACG CGAGGCTGGA TGGCCTTCCC CATTATGATT  
8040

CTTCTCGCTT CCGGCGGCAT CGGGATGCCC GCGTTGCAGG CCATGCTGTC CAGGCAGGTA  
8100

GATGACGACC ATCAGGGACA GCTTCAAGGA TCGCTCGCGG CTCTTACCAG CCTAACTTCG  
8160

10/21

FIGURE 2I

ATCACTGGAC CGCTGATCGT CACGGCGATT TATGCCGCCT CGGCGAGCAC ATGGAACGGG  
 8220  
 TTGGCATGGA TTGTAGGCGC CGCCCTATAC CTTGTCTGCC TCCCCGCGTT GCGTCGCGGT  
 8280  
 GCATGGAGCC GGGCCACCTC GACCTGAATG GAAGCCGGCG GCACCTCGCT AACGGATTCA  
 8340  
 CCACTCCAAG AATTGGAGCC AATCAATTCT TCGGAGAAC TGTGAATGCG CAAACCAACC  
 8400  
 CTTGGCAGAA CATATCCATC GCGTCCGCCA TCTCCAGCAG CCGCACGCGG CGCATCTCGG  
 8460  
 GCAGCGTTGG GTCCTGGCCA CGGGTGC GCA TGATCGTGCT CCTGTCGTTG AGGACCCGGC  
 8520  
 TAGGCTGGCG GGGTTGCCCTT ACTGGTTAGC AGAATGAATC ACCGATACGC GAGCGAACGT  
 8580  
 GAAGCGACTG CTGCTGCRAA ACGTCTGCGA CCTGAGCAAC AACATGAATG GTCTTCGGTT  
 8640  
 TCCGTGTTTC GTAAAGTCTG GAAACGCGGA AGTCAGCGCC CTGCACCATT ATGTTCCGGA  
 8700  
 TCTGCATCGC AGGATGGTGC TGGCTACCCT GTGGAACACC TACATCTGTA TTAACGAAGC  
 8760  
 CTTTCTCAAT GCTCAGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTG CTCCAAGCTG  
 8820  
 GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT  
 8880  
 CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG  
 8940  
 ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC  
 9000  
 GGCTACACTA GAAGGACAGT ATTTGGTATC TCGCTCTGCT TGAAGCCAGT TACCTTCGGA  
 9060  
 AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT  
 9120  
 GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT  
 9180

11/21

## FIGURE 2J

TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGAGA  
9240

TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC  
9300

TAAAGTATAT ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GETTAATCAG TGAGGCACCT  
9360

ATCTCAGCGA TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA  
9420

ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA  
9480

CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA  
9540

AGTGGTCCTG CAACTTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA  
9600

GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTGC AGGCATCGTG  
9660

GTGTCACGCT CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCCA  
9720

GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT  
9780

GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT  
9840

CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA  
9900

TTCTGAGAAT AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAC ACGGGATAAT  
9960

ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTT TTCGGGGCGA  
10020

AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC  
10080

AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG  
10140

CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC  
10200

12/21

FIGURE 2K

CTTTTCAAT ATTATTGAAG CATTATCAG GGTATTGTC TCATGAGCGG ATACATATTT  
10260

GAATGTATTT AGAAAAATAA ACAAATAGGG GTCCGCGCA CATTCCCCG AAAAGTGCCA  
10320

CCTGACGTCT AAGAAACCAT TATTATCATG ACATTAACCT ATAAAAATAG GCGTATCACG  
10380

AGGCCCTTTC GTCTTCAA  
10398

13/21




FIG. 3

14/21




FIG. 4

15/21

## FIGURE 5A

TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA  
60

CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG  
120

TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC  
180

ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGGCGCC  
240

ATTCGCCATT CAGGCTGCGC AACTGTTGGG AAGGGCGATC GGTGCGGGCC TCTTCGCTAT  
300

TACGCCAGCT GGCGAAAGGG GGATGTGCTG CAAGGCGATT AAGTTGGGTA ACGCCAGGGT  
360

TTTCCCAGTC ACGACGTTGT AAAACGACGG CCAGTGCCAA GCTTGCATGC CTGCAGGTGC  
420

ACTCTAGAGG ATCCGAAAAA ACCTCCCACA CCTCCCCCTG AACCTGAAAC ATAAAATGAA  
480

TGCAATTGTT GTTGTTAACT TGTTTATTGC AGCTTATAAT GGTTACAAAT AAAGCAATAG  
540

CATCACAAAT TTCACAAATA AAGCATTTTT TTTACTGCAT TCTAGTTGTG GTTTGTCCAA  
600

ACTCATCAAT GTATCTTATC ATGTCTGGAT CCCC GCGGCC GCCAAATCAT TTATTGTTCA  
660

AAGATGCAGT CATCCAAATC CACATTGACC AGATCGCAGG CAGTGCAAGC GTCTGGCACC  
720

TTTCCCATGA TATGATGAAT GTAGCACAGT TTCTGATACG CCTTTTTGAC GACAGAAACG  
780

GGTTGAGATT CTGACACGGG AAAGCACTCT AAACAGTCTT TCTGTCCGTG AGTGAAGCAG  
840

ATATTTGAAT TCTGATTCAT TCTCTCGCAT TGTCTGCAGG GAAACAGCAT CAGATTCATG  
900

CCCACGTGAC GAGAACATTT GTTTTGGTAC CTGTCTGCGT AGTTGATCGA AGCTTCCGCG  
960

TCTGACGTCG ATGGCTGCGC AACTGACTCG CGCACCCGTT TGGGCTCACT TATATCTGCG  
1020

16/21

## FIGURE 5B

TCAGTGGGGG CGGGTCTTTT CTTGGCTCCA CCCTTTTGA CGTAGAATTC ATGCTCCACC  
1080

TCAACCACGT GATCCTTTGC CCACCGGAAA AAGTCTTTGA CTTCTGCTT GGTGACCTTC  
1140

CCAAAGTCAT GATCCAGACG GCGGGTGAGT TCAAATTTGA ACATCCGGTC TTGCAACGGC  
1200

TGCTGGTGTT CGAAGGTCGT TGAGTTCCCG TCAATCACGG CGCACATGTT GGTGTTGGAG  
1260

GTGACGATCA CGGGAGTCGG GTCTATCTGG GCCGAGGACT TGCATTTCTG GTCCACGCGC  
1320

ACCTTGCTTC CTCCGAGAAT GGCTTTGGCC GACTCCACGA CCTTGGCGGT CATCTTCCCC  
1380

TCCTCCCACC AGATEACCAT CTTGTGACA CAGTCGTTGA AGGGAAAGTT CTCATTGGTC  
1440

CAGTTTACGC ACCCGTAGAA GGGCACAGTG TGGGCTATGG CCTCCGCGAT GTTGGTCTTC  
1500

CCGGTAGTTG CAGGCCCAA CAGCCAGATG GTGTTCTCT TGCCGAACTT TTTCGTGGCC  
1560

CATCCCAGAA AGACGGAAGC CGCATATTGG GGATCGTACC CGTTTAGTTC CAAAATTTTA  
1620

TAAATCCGAT TGCTGGAAAT GTCCTCCACG GGCTGCTGGC CCACCAGGTA GTCGGGGGGC  
1680

GTTTTAGTCA GGCTCATAAT CTTTCCCGCA TTGTCCAAGG CAGCCTTGAT TTGGGACCGC  
1740

GAGTTGGAGG CCGCATTGAA GGAGATGTAT GAGGCCTGGT CCTCCTGGAT CCACTGCTTC  
1800

TCCGAGGTAA TCCCCTTGTC CACGAGCCAC CCGACCAGCT CCATGTACCT GGCTGAAGTT  
1860

TTTGATCTGA TCACCGGCGC ATCAGAATTG GGATTCTGAT TCTCTTTGTT CTGCTCCTGC  
1920

GTCTGCGACA CGTGCGTCAG ATGCTGCGCC ACCAACCGTT TACGCTCCGT GAGATTCAAA  
1980

CAGGCGCTTA AATACTGTTC CATATTAGTC CACGCCCACT GGAGCTCAGG CTGGGTTTTG  
2040

17/21

## FIGURE 5C

GGGAGCAAGT AATTGGGGAT GTAGCACTCA TCCACCACCT TGTTCCCGCC TCCGGCGCCA  
2100

TTTCTGGTCT TTGTGACCGC GAACCAGTTT GGCAAAGTCG GCTCGATCCC GCGGTAAATT  
2160

CTCTGAATCA GTTTTTCGCG AATCTGACTC AGGAAACGTC CAAAACCAT GGATTTACCC  
2220

CCGGTGGTTT CCACGAGCAC GTGCATGTGG AAGTAGCTCT CTCCCTTCTC AAATTGCACA  
2280

AAGAAAAGGG CCTCCGGGGC CTTACTCACA CGGCGCCATT CCGTCAGAAA GTCGCGCTGC  
2340

AGCTTCTCGG CCACGGTCAG GGGTGCCTGC TCAATCAGAT TCAGATCCAT GTCAGAATCT  
2400

GGCGGCAACT CCCATTCCTT CTCGGCCACC CAGTTCACAA AGCTGTCAGA AATGCCGGGC  
2460

AGATGCCCCGT CAAGGTCGCT GGGGACCTTA ATCACAATCT CGTAAAACCC CGGCATGGCG  
2520

GCTGCGCGTT CAAACCTCCC GCTTCAAAT GGAGACCCTG CGTGCTCACT CGGGCTTAAA  
2580

TACCCAGCGT GACCACATGG TGTCGCAAAA TGTCGCAAAA CACTCACGTG ACCTCTAATA  
2640

CAGGACTCTA GAGGATCCCC GGGTACCGAG CTCGAATTCG TAATCATGGT CATAGCTGTT  
2700

TCCTGTGTGA AATTGTTATC CGCTCACAAT TCCACACAAC ATACGAGCCG GAAGCATAAA  
2760

GTGTAAAGCC TGGGGTGCCT AATGAGTGAG CTAATCACA TTAATTGCGT TGCCTCACT  
2820

GCCCCTTTC CAGTCGGGAA ACCTGTCGTG CCAGCTGCAT TAATGAATCG GCCAACGCGC  
2880

GGGGAGAGGC GGTTCGCGTA TTGGGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG  
2940

CTCGGTCGTT CGGCTGCGGC GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC  
3000

CACAGAATCA GGGGATAACG CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGGCCAG  
3060

18/21

## FIGURE 5D

GAACCGTAAA AAGGCCGCGT TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA  
3120

TCACAAAAAT CGACGCTCAA GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA  
3180

GGCGTTTCCC CCTGGAAGCT CCCTCGTGCG CTCTCCTGTT CCGACCCTGC CGCTTACCGG  
3240

ATACCTGTCC GCCTTTCTCC CTTGCGGAAG CGTGGCGCTT TCTCATAGCT CACGCTGTAG  
3300

GSTATCTCAGT TCGGTGTAGG TCGTTCGCTC CAAGCTGGGC TGTGTGCACG AACCCCCCGT  
3360

TCAGCCCGAC CGCTGCGCCT TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA  
3420

CGACTTATCG CCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG  
3480

CGGTGCTACA GAGTTCTTGA AGTGGTGGCC TAACTACGGC TACTAGAGAA GGACAGTATT  
3540

TGGTATCTGC GCTCTGCTGA AGCCAGTTAC CTTGCGAAAA AGAGTTGGTA GCTCTTGATC  
3600

CGGCAAACAA ACCACCGCTG GTAGCGGTGG TTTTTTTGTT TGCAAGCAGC AGATTACGCG  
3660

CAGAAAAAAA GGATCTCAAG AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG  
3720

GAACGAAAAC TCACGTTAAG GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA  
3780

GATCCTTTTA AATTAAAAAT GAAGTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG  
3840

GTCTGACAGT TACCAATGCT TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTTCG  
3900

TTCATCCATA GTTGCCTGAC TCCCCGTCGT GTAGATAACT ACGATACGGG AGGGCTTACC  
3960

ATCTGGCCCC AGTGCTGCAA TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC  
4020

AGCAATAAAC CAGCCAGCCG GAAGGGCCGA GCGCAGAAAGT GGTCTTGCAA CTTTATCCGC  
4080

19/21

## FIGURE 5E

CTCCATCCAG TCTATTAATT GTTGCCGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG  
4140

TTTGCGCAAC GTTGTTGCCA TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT  
4200

GGCTTCATTC AGCTCCGGTT CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG  
4260

CAAAAAAGCG GTTAGCTCCT TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT  
4320

GTTATCACTC ATGGTTATGG CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG  
4380

ATGCTTTTCT GTGACTGGTG AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG  
4440

ACCGAGTTGC TCTTGCCCGG CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT  
4500

AAAAGTGCTC ATCATTGGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT  
4560

GTTGAGATCC AGTTCGATGT AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC  
4620

TTTCACCAGC GTTCTGEGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT  
4680

AAGGCGACA CGGAAATGTT GAATACTCAT ACTCTTCCTT TTTCAATATT ATTGAAGCAT  
4740


TTATCAGGGT TATTGTCTCA TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA  
4800

AATAGGGGTT CCGCGCACAT TTCCCCGAAA AGTGCCACCT GACGTCTAAG AAACCATTAT  
4860

TATCATGACA TTAACCTATA AAAATAGGCG TATCACGAGG CCCTTTCGTC  
4910

20/21

FIG. 6



21/21




FIG. 7

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C12N 15/86, 15/87 // C07K 14/435, 14/775</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 96/13598</b> <b>(43) International Publication Date:</b> 9 May 1996 (09.05.96)
<b>(21) International Application Number:</b> PCT/US95/14018 <b>(22) International Filing Date:</b> 27 October 1995 (27.10.95) <b>(30) Priority Data:</b> 08/331,384 28 October 1994 (28.10.94) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/331,384 (CIP) Filed on 28 October 1994 (28.10.94) <b>(71) Applicant (for all designated States except US):</b> THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 133 South 36th Street, Philadelphia, PA 19104-3246 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WILSON, James, M. [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US). KELLEY, William, M. [US/US]; 14 Hemlock Road, Lansdowne, PA 19050 (US). FISHER, Krishna, J. [US/US]; 4006 Pine Street, Philadelphia, PA 19104 (US).	<b>(74) Agents:</b> BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, Spring House, PA 19477 (US). <b>(81) Designated States:</b> AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <b>(88) Date of publication of the international search report:</b> 15 August 1996 (15.08.96)	

**(54) Title:** HYBRID ADENOVIRUS-AAV VIRUS AND METHOD OF USE THEREOF

**(57) Abstract**

The present invention provides a hybrid vector construct which comprises a portion of an adenovirus, 5' and 3' ITR sequences from an AAV, and a selected transgene. Also provided is a hybrid virus linked via a polycation conjugate to an AAV *rep* gene to form a single particle. These trans-infection particles are characterized by high titer transgene delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome. Also disclosed is the use of the hybrid vectors and viruses to produce large quantities of recombinant AAV.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

# INTERNATIONAL SEARCH REPORT

In national Application No  
PCT/US 95/14018

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/86 C12N15/87 //C07K14/435,C07K14/775

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 24641 (UNITED STATES OF AMERICA) 9 December 1993 cited in the application see page 8, line 14 - line 18 ---	1-26
X,P	WO,A,95 06743 (UAB RESEARCH FOUNDATION ) 9 March 1995 see the whole document ---	1-26
X,P	WO,A,95 23867 (RHONE-POULENC RORER S.A.) 8 September 1995 see the whole document -----	1-26

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

- \* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* "&" document member of the same patent family

Date of the actual completion of the international search

7 June 1996

Date of mailing of the international search report

26.06.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Skelly, J

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/US 95/14018

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9324641	09-12-93	AU-B- 4598193 CA-A- 2136441 EP-A- 0644944	30-12-93 09-12-93 29-03-95
WO-A-9506743	09-03-95	AU-B- 7565694	22-03-95
WO-A-9523867	08-09-95	FR-A- 2716893 AU-B- 1852695	08-09-95 18-09-95